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Abstract 
Quinolone derivatives have recently been introduced as inhibitors of eukaryotic 
topisomerase-11 with potential anticancer activity. In an attempt to discover novel 
quinolones with potential anticancer properties, compound A, a clinical candidate with 
drug-like properties in different animal models, attracted our attention. Based on 
molecular modeling study using Alchemy-3™, compound B was designed in such a way 
that at its optimized steric/energetic configuration it overlapped perfectly with compound 
A. 
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Figure 1.0- Structures of compounds A , B, and derivatives of compound B 
Different synthetic methodologies were utilized to synthesize compound B (6a) 
and its N1-analogues (6b-n). During the structural optimization, a Mitsunobu-type 
reaction was used for regioselective N1-alkylation of quinolones. orne of the final 
products (6a, 6c, 6k) and intermediates (4d and 13a,b,f) were randomly screened for 
possible cytotoxic activity on different cancer and normal cell lines at 100 jlg/ml 
concentration. The preliminary results indicate the cytotoxic potential of this class of 
compounds, especially compound 6c, but a more detailed structure-activity relationships 
study is needed to confirm this hypothesis. 
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1- Introduction 
Following cardiovascular diseases, the group of diseases referred to as "cancer" is 
the second cause of premature mortality worldwide. The occurrence of cancer is related 
to a variety of factors such as gender and age. The North American Association of 
Central Cancer Registries (NAACCR) provides statistical data on cancer incident and 
mortality in North America. 1 Table 1 shows the incident of the five most commonly 
diagnosed cancers in North America. 
Types of cancer Incidents per year (for all races and both sexes) 
prostate 167,673 
female breast 162,228 
lung 161 ,007 
colon and rectum 126,190 
bladder 50,289 
Tablel-1. Types of cancer versus the incident per year during the five year period of 
1999 to 2003. 
Breast cancer is more common in females and leukemia is the most predominant 
cancer in children. Among the different types of cancer, lung cancer is the main cause of 
death in adults. The most common cancer in males after prostate cancer, is lung cancer. 
The overall incidence rate of cancer in North America was found to be 35% higher 
among men than women. However, the difference in percentages of incidence can differ 
greatly based on race groups. 1-2 
During 1999-2003, a total of 233,840 Canadians died of cancer, approximately, 
128 deaths per day. Fifty-three percent of Canadian cancer deaths occurred among men 
and 4 7% occurred among women. 1 
Environmental factors and life-style have played a major role in the incidences of 
many cancers. Around 75% of cancers are thought to be caused by enviromnental 
carcinogens such as ionizing radiation and chemicals. 3 
Genetic factors also play a major role in development of cancer. The presence of 
certain genes may lead cells to begin their uncontrolled growth. Mutations in genes 
resulting in malignancy can be either acquired or inherited. There is a period of time 
known as the latency period between exposure to a carcinogen and appearance of 
symptoms. The latency period varies from months to decades in different individuals, 
depending on the cancer type and the susceptibility of the person. 4 
1.1- Biology of cancer 
During cell cycle, cells replicate to produce two genetically identical daughter 
cells. Cell division is a highly regulated process which maintains tissue homeostasis and 
in which, new cells replace damaged cells. A human being consists of an average of 
100,000 billion cells. 
The cell cycle consists of four phases: (1) G 1, the first growth phase (gap I 
period); (2) DNA synthesis phase (S) which comes after G 1 and for which there is a 
2 
second gap period (growth phase) after S; (3) nuclear and cell division phase is called the 
M phase; and ( 4) in which, the cell can enter a resting state, named G0. Depending on the 
signal that a cell receives, or the cell type, the cell cycle phases might change. The tumor 
suppressor gene, RB, produces, RB proteins, which regulate the point at which cells stop 
replication of their DNA. RB functions as a control switch for the S phase. The cell cycle 
regulating system includes various proteins, among which two groups are of very high 
importance, the cyclins and the cyclin-dependent kinases (CDKs). CDKs are 
serine/threonine protein kinases that are capable of binding to their regulatory subunits 
and become catalytically active. Different members of CDK family are activated by the 
appropriate cyclins, during certain phases of the cell cycle. 5 
Disruption of a normal cell cycle will result in inappropriate cellular replication 
that can be caused by most cancer-causing genes. "Malignant stimuli activators signal 
pathways that allow progression through G1 and then G1/S transition. G1 is the phase of 
the cell cycle wherein the cell is responsive to growth factors . Control of the G1 into G1 /S 
transition is often disrupted in cancer cells."5 The most important part involved in the 
G 1/S transition is the phosphorylation of RB. Phosphorylation of RB will cause the 
release of E2F (a fan1ily of transcription factors) . Three types of E2F including E2Fl , 
E2F2 and E2F3a are cell cycle activators. There are six other E2F factors that are cell 
cycle suppressors (E2F3b, E2F4-8). 5 
The RB pathway is often disrupted m human cancer. The non-functional RB 
pathway might from inappropriate activation of CDK/cyclins. The concentrations of 
CDKs usually remain constant within the period of a cell cycle. However, concentrations 
3 
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of cyclins fluctuate during progression of the cell cycle. CDKs might go through 
mutation, which could result in cancer. Higher intensities of CDK4 might occur in 
melanoma, sarcoma, and glioma. Non-functional expression of cyclin has been reported 
in some human cancers such as breast bladder and lung. 5 
A cancer process can be defined by its initiation, promotion, and progression. The 
initiation includes an irreversible damage to DNA that can correspond to the cancer. The 
biochemical process in which an already initiated cell, tissue, or organ develops focal 
proliferation is called promotion. The process of progression is irreversible. During the 
progression process, there is further growth and expansion of the malignant cells over 
normal cells. 
1.2- Cancer treatment 
Cancer has been traditionally treated with surgery. Recent developments have led 
to improvement in other treatments such as chemotherapy, radiotherapy, and 
immunotherapy. Surgery is usually the primary treatment for resection of the localized 
cancer; however, chemotherapeutic agents are now considered of great value in the 
treatment of a variety of malignancies such as leukemia, Hodgkin' s lymphoma, liver 
cancers and metastatic colon cancer. 6 
1.2.1- Chemotherapy 
Chemotherapy is used for a variety of purposes such as to: 
1- Cure cancer; 
4 
2- Reduce size of a specific tumor before surgery; 
3- Prevent micrometastasis; and/or 
4- Make the malignant tissues sensitive to therapy (prior to radiotherapy). 
The problem with chemotherapy Is the relatively high toxicity of 
chemotherapeutic agents. Normal cells are also affected, and the lack of selectivity for 
the malignant tissues and development of drug resistance may complicate their 
usefulness. Rapid proliferating cells including hair cells, bone marrow and 
gastrointestinal cells are in more danger at the time of exposure to chemotherapeutic 
drugs than slow proliferating cells. 
Another complication caused by cancer chemotherapeutic agents is the 
irreversible DNA damage. Patients who survive chemotherapy are at risk of iatrogenic 
cancers. An example of a high risk chemotherapeutic agent is cyclophosphamide. It can 
chemically react with DNA in the same way that some carcinogens do. The risk of 
iatrogenic cancer depends on the cumulative dose of a drug in a patient, which makes 
younger patients more susceptible to the drug' s adverse effects and resistance7 -8 
1.2.2- Classes of antineoplastic agents 
Antineoplastic agents are classified m the following way, based on their 
mechanism of action. 
1- Alkylating agents 
2-Antimetabolites and nucleoside analogues 
3-Antitumor antibiotics 
5 
4-Antimitotic agents 
5- Hormones and antagonists 
6-Miscellaneous agents 9 
1.2.2.1-Alkylating agents 
Alkylating agents were the first reported class of compounds with antitumor 
activities. Between World Wars I and II, studies of chemical and biological properties of 
nitrogen mustards took place. 6 The first anticancer compound approved by FDA in 1949 
for clinical use was mechlorethamine (nitrogen mustard). 9 
Alkylating agents exhibit their effect, namely, via disruption of DNA functions 
and causing cell death, through three different mechanisms. In the first mechanism, an 
alkylating agent attacks a nucleophilic site such as (N-7) of a purine base (guanine 
residue) and alkylates it. As a result, alkylated bases prevent further DNA synthesis and 
RNA transcription. The second mechanism involves formation of cross-bridges from two 
bases that are linked together by an alkylating agent. These cross-bridges can form by 
alkylating agents that possess two binding sites for DNA. A cross-bridge may connect 
two different DNA strands (inter-DNA) or can be formed within one DNA double helix 
(intra-DNA). 
In a normal DNA double helix, adenine always pairs with thymine and guanine 
pmrs with cytosine. In the third mechanism, alkylating agents cause mispairing of 
nucleotides which results in mutation. The common property of alkylating agents is their 
being strong electrophiles. They can form carboniun1 ions, aziridinium intermediates, or 
6 
transition-metal complexes with DNA. Therefore, the chemotherapeutic effect of these 
compounds is relevant to their potency in DNA alkylation. Alkylating agents are mostly 
efficient in G1 or S phases of the cell growth. These agents can be categorized as 
mechlorethamine (nitrogen mustards), ethyleneimines and methylmelamine, alkyl 
sulfonates, nitrosoureas, and triazenes. 6-9 
1.2.2.2- Antimetabolites and nucleoside analogues 
Antimetabolites are structural analogues of naturally-occurring compounds that 
can prevent biosynthesis of metabolites in cells. Their mechanism of action involves 
interfering with production of nucleic acids. Antimetabolites can work through different 
mechanisms including competition for binding sites on enzymes. There are three 
categories of antimetabolites : antifolates (e.g. methotrexate), purine analogues (e.g. 6-
mercaptopurine) and pyrimidine antimetabolites (e.g. 5-fluorouracil). 6 
Antimetabolites in general, inhibit cell growth in the most rapidly proliferating 
cells such as bone marrow. Folic acid is essential in the synthesis of DNA and RNA 
precursors, including thymidylate and purines. The enzyme dihydrofolate reductase 
(DHFR) is the primary target for folate antimetabolites such as methotrexate used in 
cancer therapy. Folic acid is reduced by DHFR in two steps. The reduced form of folic 
acid (tetrahydrofolic acid) is involved in transferring a single carbon unit such as methyl 
or formyl group in biosynthetic pathways of pyrimidine- and purine-based natural 
nucleosides. Inhibition of DHFR results in lack of cofactors required for the synthesis of 
purines and thymidylate in tumor cells. 9 
7 
There is one major anticancer drug in the category of purine analogues, namely, 
6-mercaptopurine. 6-Mercaptopurine is an analogue of hypoxanthine. Purine analogues 
work on multiple sites and their toxicity mechanism is the result of combined effects on 
different sites. 9 
5-Fluorouracil, the principal pyrimdine antimetabolite, is an inhibitor of 
thymidylate synthase, which is the key enzyme in the synthesis of thymidine from 
uridine. 6 
1.2.2.3- Antitumor antibiotics 
Most of the compounds in this class were originally developed as antibiotics but 
these were rejected because of their toxicity . 9 Actinomycin A was the first one in this 
category and was isolated from streptomyces by Walksman and Woodruff in 1940. 
Antitumor antibiotics interact with DNA through several pathways including 
intercalation, DNA strand breakage and inhibition oftopoisomerase type II. 6 
Dactinomycin is an example of an antitumor antibiotic. The structure of this 
compound consists of a phenoxazone ring and two cyclic pentapeptides. The presence of 
the phenoxazone ring gives a red color to the drug. Dactinomycin can bind to DNA and 
block chain elongation. The phenoxazone chromophore part of the drug structure, 
intercalates between bases in the DNA and the 2-amino group of the guanine. This 
mechanism was found to be very important for the formation of DNA-drug complexes. 
Tight binding between DNA and drug makes the DNA-drug dissociation a very slow 
process. Dactinomycin inhibits DNA directed RNA synthesis at low concentrations. In 
8 
higher concentrations, DNA synthesis is also affected. Other examples of antitumor 
antibiotics include the beleomycins, mitomycin C, and the anthracylines. 6-9 
1.2.2.4- Antimitotic agents 
Antimitotic agents in general, prevent cellular mitosis. The biological activity of 
this group depends on their ability to bind specifically to tubulin and to block 
polymerization of microtubules. The first antimitotic agents were vinca alkaloids, whose 
mechanism of action was suggested to proceed through their specific binding to tubulin. 
Tubulin dimers are unable to aggregate and fom1 microtubules when bound with vinca 
alkaloids. This mode of action results in a shift of the biological equilibrium toward 
disassembly of microtubules and their shrinkage. 9 
1.2.2.5- Hormonal therapies and hormone antagonists 
Manipulation of hormones is another approach in the treatment of hormonal-
related cancers. This group of compounds can be categorized as antiestrogens, GnRH 
(Gonadotropin- releasing hormone) agonists and antiandrogens. The most common 
example nowadays is the treatment of breast cancer with antiestrogen drugs such as 
Tamoxifen.9 Flutamide is an example of an antiandrogen that is approved by FDA for the 
treatment of prostate cancer. 9 
An example of hormonal therapy to treat metastatic prostate cancer is the use of 
gonadotropine-releasing hormone agonists. The goal in this therapy is to exclude the 
9 
stimulation caused by male hormones on cancer cells. Employment of gonadotropin-
releasing hormone agonist causes a decrease in testosterone through down regulation. 
1.2.2.6- Cancer immunotherapy 
The main goal of cancer immunotherapy is to stimulate the patient's immune 
system to attack the malignant twnor cells that are responsible for the cancer. It can be 
through adminstration of therapeutic antibodies or by immunization of the patients, in 
which the patient's own immune system is trained to distinguish the cancerous cells as 
targets. In immunotherapy, the adminstration of antibodies helps the immune system to 
destroy the tumor cells. Although the tumor cells are the patient' s own cells that are 
spreading out of proper regulatory control, most of them display unusal antigens that are 
not appropriate for the cell type. For instance, glycosphingolipid GD2 which is only 
expressed at the outer surface membranes of neuronal cells is expressed on the surfaces 
of a wide range of tun1or cells including neuroblastoma, medulloblastomas, astrocytomas, 
melanomas, small-cell lung cancer, osteosarcomas and other soft tissue sarcomas. 
Therefore, GD2 could be a suitable tumor-specific target for immunotherapy. Raising 
antibodies against specific antigen becomes possible via utilization of monoclonal 
antibody technology. A list of FDA-approved monoclonal antibodies is mentioned in 
Table (1.2).10 
10 
Brand [Approval Antibody Type Target Approved treatment(s) 
name date 
Cam path 2001 Alemtuzumab humanized CD 52 Chronic lymphocytic leukemia 
vascular 
Avastin 2004 Bevacizumab humanized endothelial colorectal cancer 
growth factor 
epidermal 
Erbitux 2004 Cetuximab chimeric growth factor colorectal cancer 
receptor 
Gemtuzumab acute myelogenous Mylotarg 2000 
ozogamicin humanized CD33 leukemia (with 
calicheamicin) 
non-Hodgkin 
Zevalin 2002 lbritumomab CD20 
lymphoma (with 
iuxetan munne yttrium-90 or indium-
111) 
epidermal 
Vectibix 2006 Panitumumab humanized growth factor colorectal cancer 
receptor 
Rituxan, 1997 Rituximab chimeric CD20 
non-Hodgkin 
Mabthera lymphoma 
Herceptin 1998 Trastuzumab humanized ErbB2 breast cancer 
Table 1.2- "Cancer immunotherapy: Monoclonal antibodies" 10 
11 
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1.2.2.7- Miscellaneous agents 
In addition to the above, there are other antineoplastic agents such as 
podophyllotoxins, epipodophyllotoxins (Etoposides), hydroxyurea, mitotane, retinoids, 
camptothecins and porfimer. 6-9 
Epipodophyllotoxins are extracted from podophylum peltatum. Etoposide and 
teniposide are semisynthetic glycosidic derivatives of podophyllotoxin. Etoposide and 
teniposide are inhibitors of topoisomerase II. Epipodophyllotoxins form complexes with 
DNA and topoisomerase II, consequently the enzyme remains bound to the free end of 
DNA. Accumulations of DNA breaks cause cell death. Etoposide and teniposide have a 
similar mechanism of action. However, teniposide's uptake by cells is faster than 
etoposide, which might be due to its higher lipophilicity. 6 
1.3- Quinolones and their nomenclature 
Quinolones are heterocyclic compounds that are formally derived from pyridones 
by fusion with a benzene ring. The systematic and official IUPAC name for 4-quinolones 
is 4- oxo-1 , 4-dihydroquinolines. However, these series of compounds are still recognized 
in the area of pharmaceutical and medicinal chemistry by their traditional name, 
quinolones. 
In order to name the quinolones properly, the position of pyridone and benzene in 
the fused heterocyclic ring system is of importance. If the pyridone is a 4-pyridone and 
the benzene ring is fused in position [2,3] or [b] , we obtain the title compound, 4-
quinolone, which is capable of a typical keto-enol tautomerism (Figure 1.1 ). 11 
12 
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Figure 1.1- Keto (la) and enol (lb) forms of quinolone structures in general. 
Even though the physicochemical evaluations are mostly in favor of the keto-
form, the majority of textbooks and articles represent quinolones as hydroxyquinolines. 
The quinolone-hydroxyquinoline tautomerism has been established based on the 0 - and 
N-ethyl derivatives obtained after ethylation of quinolones using different reaction 
conditions (Figure 1.2). 12" 13 
0 
R1=H,Me,Et 
R=H,COOR 
R 
# 
N 
Figure 1.2- 0- and N- derivatives of quinolones 
R 
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1.4- Quinolone derivatives 
To date, about 10,000 derivatives of 4-quinolone have been described. One 
review alone covers 231 types of quinolone-3-carboxylic acid derivatives that were 
reported in the period of 1939 to 1989.14 
In the beginning, the interest in 4-quinolones was extensively directed toward 
their synthesis as antimalarial agents. The discovery of 4-quinolones as antimalarial 
agents goes back to World War II. However, none of the 4-quinolones were evaluated in 
anti-malarial screening during World War II. As a result of expanding research on 4-
quinolones synthetic antimalarial drugs based on quinoline nucleus were discovered. The 
first quinoline-antimalarial agent introduced to the clinics was Chloroquine (Figure 
1.3).'5 -16 
Cl 
Figure1.3- Chloroquine 
The quinolones have been further developed since the discovery of nalidixic acid 
by Lescher. Nalidixic acid was a first-generation quinolone antibacterial, produced 
synthetically in 1962. It only had modest antibacterial activity again t gram-negative 
species and showed poor oral bioavailability. Nalidixic acid and its subsequent 
14 
derivatives, show narrow spectra of activity that restrict their clinical applications. In the 
mid-1980s, fluoroquinolones were discovered as potent, broad-spectrum antibacterial and 
chemotherapeutic agents. 
Improvement of antibacterial activity against gram-negative bacteria was 
achieved by introduction of a piperazinyl group at the C-7 position of the quinolone 
which improved the physiochemical properties of these compounds and, as a result, 
enhanced their penetration into the bacterial cell. Addition of fluorine to the C-6 position 
of quinolones resulted in dramatic increase of the activity of these compounds again t 
gram-positive bacteria (Figure 1.4). Improved pharmacodynamic and pharmacokinetic 
profiles have resulted in much better efficacy and tolerability of flourquinolones.17' 18 
G.t-is 
I 
N 
0 
0 
o o_ 
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Figure 1.4-Structures of nalidixic acid and ofloxacin 
Recently, pharmaceutical companies have tried to develop newer generations of 
quinolone antibacterials with the goal of enhancing their activities against gram-po itive 
or anaerobic bacteria. There are also new forms of quinolones designed to be active as 
antiviral and antitumor agents, as well. 
15 
1.5. General physicochemical properties of quinolones in different environments 
It is of high importance to investigate the physiochemical properties of quinolones 
in a variety of environments, especially in vivo. These studies will help in understanding 
the nature of their pharmacologic properties such as antibacterial or anticancer activities. 
Quinolone antibacterials are regularly prescribed because of their safety and good 
tolerance in patients. In general, antibacterial activity is pH dependent. The pH-dependent 
activity is due to the fact that these drugs act as bacterial DNA gyrase inhibitors and that 
the inhibition process depends on pH and acid concentrations. 19 
Quinolone behavior in vivo is particularly influenced by the degree of ionization, 
which is often shown by charged groups and affects the biological activity.20 Generally, 
complexes between quinolones and divalent cations are formed in a I : 1 ratio in which the 
4-oxo and 3-carboxylic acid functions of the quinolones make an ion-dipole interaction 
with the divalent cation (Figure1.5). 21 
In some quinolones such as nalidixic acid (NAL), flumequine (FLU), and oxolinic 
acid (OXO), the 3-carboxyl group is the only appropriate ionizable functional group. But 
in other cases like ofloxacin (OFL), norfloxacin (NOR), and enoxacin (ENO) both the 3-
carboxyl group and the N-4 of the 7-piperazinyl moiety are ionizable functional groups 
(Figure 1.5). 22 
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Figure 1.5- Examples of pH -dependence, and ionizable functional groups in quinolones 
Bacterial DNA gyrase is responsible for the introduction of negative supercoils 
into DNA, which results in the highly condensed three-dimentional structure of the 
chromatin. This mechanism is essential to condense the bacterial genetic material. 
Quino]ones in general, are DNA gyrase inhibitors. Studies have shown that interaction of 
quinolones with DNA gyrase in the absence of DNA is not possible. Complex formation 
between quinoJones and a divalent cation (e.g. Mg+2) is critical for their biological 
17 
activity. The ability of these drugs to interact with some cellular components is mediated 
by this complexation. Furthermore, the amount of quinolone bound to DNA is regulated 
by Mg2+ concentration.23 Quinolones are reported to induce photosensitivity reaction in 
human skin, but the exact mechanism is not yet known. 24 
Quinolones are reported to be photocarcinogenic that might be due to their ability 
to interact with DNA. 22 
1.6- Naturally occurring quinolones 
The quinolone skeleton can be found in a large number of compounds. There are 
examples like zoochromes which are compounds of animal basis that are responsible for 
(often changing) coloration of animal species. Other examples are contained in the 
Mediterranean sponge Verongia aerophoba Schmidt which contains uranidine and an 
antibacterial acid. Another example is an isomeric antibacterial acid in the Antarctic 
sponge Dendrilla rnembranosa (Aplysina) (family Verongidae). 25 
R' 
N R3 
H 
Uranidine, found in Verorgia aercpholxl Schmidt ~=0-1, R, = R2 Hand ~=H 
Antibacterial COI11JOUI1d found in VerorgiaaercpholxlSchmidt: R1 =1-1, Rz land~ 
Antibacterial COI11JOw1d found in Dendrilla n'l:!branosa (Aplysina): R, =01-1, ~ = H ru1d R3 1-1 
Figure 1.6- General structure of antibacterial compounds found in Verongia aerophoba 
and Dendrilla membranosa. 
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There are other quinolones that have been isolated from natural sources, such as 
echinopsin which was isolated from the seeds of Equinopsis Rita linn. This compound is 
also a decarboxylation product of 1-methyl quinolin-4(111)-one-3-carboxylic acid which 
is thought to be originated from degradation of the alkaloids meliopine, meliocopidine, 
and meliocopicine. These alkaloids have been extracted from Melicope fareana 
(Rutceae). 1-Methyl-4-quinolone-3-carboxylic acid is also formed by oxidation when 
concentrated nitric acid reacts with the above mentioned alkaloids. 26 
0 0 
N 
I 
Me 
Echi nopsine 3-carboxylic acid derivative melicopine 
Figurel. 7- Alkaloids extracted from Melicope fare ana 
The alkaloid Japonine isolated from the underground parts of Orixa Japonica is 
also a quinolone. 27 
MeO 
Figure 1.8- Japonine 
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Several other quinolone alkaloids are also known. 28 Varieties of 2-alkyl-4-
quinolones were found in plant organs and most of them showed biological activity. One 
example is evocaprine which is isolated from Evodia rutaecarpa. 29 
I Alkyl I 
Me Me 
2-alkyl-4-quinolone cvocaprine 
Figure1.9- Evocaprine , an example of2-alkyl-4-quinolone 
Derivatives of acridone known as acrimarines are alkaloids from Melicope Jarena. 
Acrimarines are found in Citrus fudako (Rutaceae) and acridone itself is a component of 
the roots and rhizomes of Thamnosa montana (Rutacea). Different derivatives are 
differentiated by the position of the R substituent as well as the presence or absence of 
methyl groups at the 3, 5, 6 and 9 positions of the acridine ring (Figure 1.1 0).30 
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20 
Me 
0 0 
Acrimarine A, 2= R *, 3=H, 4=H, 5=Me, 6=Me, 9= Me 
Acrimarine B, 2= R *, 3=Me, 4=H, 5=Me, 6=Me, 9=H 
Acrimarine C, 2= H, 3= Me, 4=R *, 5=Me, 6=H, 9= H 
Acrimarine D, 2= H, 3=Me, 4=R *, 5=Me, 6=Me, 9=H 
Acrimarine E, 2= R *, 3=Me, 4=H, 5=Me, 6=H, 9=H 
Acrimarine F, 2= R *, 3=Me, 4= H, 5=Me, 6= 1-1, 9=Me 
Acrimarine G, 2= R* , R= l-1 , 4= 1-1 , 5= 1-1 , 6=de-0Me, 9=Me 
Acrimarine H, 2= R *, 3=Me, 4=1-1, 5=1-1 , 6=de-0Me, 9=Me 
Figure 1.10- Derivatives of Acridone 
There are other acridone alkaloids (e.g. acronycme, acropoline, acropylidine) 
isolated from the root bark of Severinia buxifolia Tenore (Rutaceae) that are called 
buxifoliadines. 
0 0 
0 OMe 
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0 ~ M~ Me Me Me Me Me OH 
Acronycine Acropoline Acropylidine 
Figurel.ll- Examples of acridone alkaloids isolated from Severinia buxifolia 
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Significant antineoplastic and antitumor activity for these compounds have been 
reported. Acronycine was found in Acronychia baueri (Bauerella baueri), Melicope 
letococca, Sarcomelicope leiocarpa and S.argyrophylla(Rutaceae). Acropline is formed 
via dehydrogenation of acropylidine. 29 
1. 7- Synthesis of quinoline-4-ones 
Synthetic methodologies have been categorized based on how the ring closure 
procedure leads to the formation of the quinolone nucleus. Starting materials are often 
benzene and in exceptional cases, pyridine derivatives? 4 
Preparations of 4-quinolones basically follow the same principles as with 
quinoline syntheses, since they are modified versions of the quinolines, having a ketone 
group at position 4. Quinolones have been known for a long time and have been 
synthesized in many ways. They are stable compounds and were fir t i olated from coal 
tar in 1834. They are normally high boiling point liquids or low m lting point solids with 
a sweetish odor. 3 1 The general procedures which are often used for the synthesis of 
quinolines are applicable for quinolones with few exceptions. Major routes proceed via 
C4-C4a and C&a-N bond formations . 32 
1.7.1- Camps quinoline synthesis 
In this procedure, alkaline cyclization of an N-acylated-o-aminobenzophenone 
affords the corresponding 2- or 4- hydroxyquinolines (Scheme 1.1) 33-40 
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Scheme 1.1- Camps quinoline synthesis 
1.7.2- Combes and Doebner-Miller quinoline synthesis 
0 R' 
C)NH:R'DO-H,O QN~R 
R 
Scheme1.2- Combes quinoline synthesis 
The Doebner-Miller (Beyer Method for quinolines) and Combes syntheses are 
both known to be quite general for the production of quinoline derivatives (Scheme 
1.2). 4 1-45 
The similarity in their mechanism of formation, particularly at the cyclization 
step, between the Doebner-Miller and kraup syntheses were described in several articles 
(Scheme 1.3). 4649 
R 
Scheme1.3- Doebner-Miller (Beyer Method) quinoline synthesis 
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1. 7.3- Riehm quinoline synthesis 
The Riehm quinolone synthesis has much in common with the Doebner - Miller 
synthesis. The reaction products are derived from acetone and aniline hydrochloride, the 
condition that is often suitable for the formation of quinolines from carbonyl compounds 
and aniline (Scheme 1.4) so-56 
Heat 
AICI3 ~ N 
Scheme1.4- Riehm quinoline synthesis 
1.7.4- Gould-Jacobs reaction. 
Another main procedure used to obtain both quinolines and quinolones is the 
Gould-Jacobs reaction, according to the following scheme. In this procedure, ring closure 
occurs at a very high temperature (Scheme 1.5). 57-60 
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Schemel.S- Gould-Jacobs quinolone synthe is 
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1.7.5- Bond formation in 4-quinolone synthesis 
As a rule, creation of 4-quinolones is performed by pyridine ring formation using 
different ring closure reactions. This will allow us to classify the ring closures 
N ring closures. 
Bond formation between N 1-C2 has been mentioned more in the synthesis of 
naphthyridones than the quinolones. The reaction is carried out between a haloaniline and 
a terminal alkyne, in the presence of palladium as a catalyst. This type of reaction yield 
2-substituted 4-quinolones as the main products (Scheme 1.6). 61 
R Pd(O) 
II R 
Scheme1.6- Quinolone synthesis through N 1-C2 bond formation 
Ester condensation with acid anhydride or with derivatives of 2-nitrobenzoyl 
chloride followed by cyclization is another approach to prepare N1-C2 quinolones 
(Scheme 1. 7). 62-63 
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Scheme1.7- Quinolone synthesis through N 1-C2 bond formation 
The modified Niementowski quinoline synthesis is the procedure to synthesize 
C2-C3 quinolones. Starting material for this reaction is an anthranilic acid derivative that 
will be activated via its acid anhydride, which after a ring opening-ring closure sequence 
affords 2-substituted - quinolone as shown below (Scheme 1.8). 64 
ex,=- oc~-R. -
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Scheme 1.8- Modified Niementowski reaction 
For C3-C4 quinolone formation, Dieckmann cyclization of Schiff bases can work 
well, especially for 2- and 3- substituted 4-quinolones (Scheme 1.9). 65 
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Scheme 1.9- Quinolone formation through Dieckmann cyclization of chiff bases 
Condensation of anthranilic acid in basic condition with carbonyl compounds 
gives rise to 2- and 3-substituted-4-quinolones (Scheme 1.1 0). 
0 0 
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Scheme 1.10- Formation of2- and 3- substituted-4-quinolones after cyclization 
To prepare 2-arylsubstituted quinolones, there is a method which starts with 
making Schiff bases derived from N,N-dialkylarnides of anthranilic acid and substituted 
acetophenones. Ring closure of the Schiff base results in the formation of the desired 2-
arylquinolone (Scheme 1.11). 66 
Ar 
Scheme 1.11- Formation of2-aryl-4-quinolones through Schiff base preparation 
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N-Aroyl-a-aminoacetophenones, after being treated with potassium 2-methyl-2-
popanolate, can easily cyclize to 2-aryl-4-quinolones (Scheme 1.1 2). 67 
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Scheme 1.12- Cyclization of2-aryl-4-quinolones 
One of the most impotiant approaches in the synthesis of N-substituted-4-
quinolones is to use suitable diesters to undergo Dieckmannn cyclization in basic 
conditions. This reaction will give tetrahydroquinolines that could be further oxidized to 
give the favorable 4-quinolones (Scheme 1.13 ). 68 
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Scheme 1.13- Synthesis ofN-substituted-4-quinolones 
The oldest route to make 4-quinolones is bond creation between C4-C4a which 
more often involves a thermal cyclization of an activated enaminone (Scheme 1.14). 
Non-selectivity of this procedure is its major problem. In this respect, selection of 
appropriately substituted aniline may help to overcome the non-selectivity problem. 73 
28 
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Scheme 1.14- Preparation of quinolones by bond formation between C4-C4a 
1.7.6- Conrad-Limpach reaction for 4-quinolone synthesis 
Another name reaction that is used to make 4-quinolones is the Comad-Limpach 
reaction (Scheme 1.15), which is basically performed by reacting aniline and 3-
oxobutanoate below 100 °C. The reaction proceeds further by cyclization in an inert 
solvent, at high temperature (above 250 °C). In this situation, if the first step is done 
above 100 °C, the amide of 3-oxobutanoic acid would form, which upon further 
cyclization, gives rise to a product of Knorr reaction which is 2-quinolone instead of 4-
quinolone. 69 
Scheme 1.15- Comad-Limpach reaction 
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In order to place an aromatic group as a substitution on the quinolone ring, the 
Conard-Limpach reaction would be an option (Scheme 1.1 6). 70 
0 
R(Ar) 
Scheme 1.16- Aromatic group substitution on the quinolone ring by Conard-Limpach 
reaction 
1.7.7- Modified Gould-Jacobs reactions for the synthesis of 4-quinolones 
The most famous name reaction in synthesizing quinolones is the Gould-Jacobs 
reaction (Scheme 1.17). The reaction starts with a nucleophilic substitution which then 
d . h I 1. . 60-61 7 1-73 procee s v1a a t erma eye 1zat10n. ' 
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Scheme 1.17- Modified Gould-Jacobs reaction 
The open-chain intermediate is an activated aminoethylene derivative that 
sometimes can be isolated but most of the times it is used directly for the next thermal 
cyclization. Recently, a one pot synthesis of 4-quinolones using microwave radiation has 
been reported. 74 
30 
In cases of thermal cyclization above 140 °C, solvents such as low melting point 
biphenyls are frequently employed. The thermal cyclization step can be done in an inert 
atmosphere, or at reduced pressure as well. Success of the thermal cyclization step 
depends highly on the purity of the open-chain intermediate. 
In order to make N-substituted quinolones, modified Gould-Jacobs reactions have 
been developed. In such cases, the open-chain intermediate no longer carries a hydrogen 
atom, thereby thermal cyclization looks impossible. These intermediates are cyclized in 
acidic media such as sulfuric acid, acetic anhydride, or trifluoroacetic anhydride (Schem 
1.18). 
~ 0 OR' 
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Scheme 1.18- ynthesis of N-substituted quinolones by modified Gould-Jacobs reaction 
After recognizing the antibacterial properties of nalidixic acid, the Gould-Jacobs 
reaction became the main production pathway for compound with similar or related 4-
31 
quinolone structures. Alkylation (ethylation) was done in basic conditions (K2C03 or 
NaH) in the presence of ethyl iodide. Subsequent hydrolysis is needed to transform the 
ester to the free acid (Scheme 1.19). 75 
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Scheme 1.19-Synthesis of nalidixic acid 
0 
Esters of2-alkylthio-4-quinolone-3-carboxylic acids were also prepared from 
arylisothiocyanates and diesters, after alkylation and cyclization (Scheme 1.20). 76 
0 
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Scheme 1.20-Formation of 2-alky lthio-4-quinolone-3 -carboxy lie acids 
N 1-C8a bond formation is the most favorable procedure for the syntheses of 
naphthyridones, due to the high reactivity of the carbon adjacent to the pyridine nitrogen, 
and, the facile departure of the halogen positioned on this carbon. Aroylacetate forms, as 
the starting materials are prepared from the corresponding acids. Usually, acids are first 
converted to acid chlorides then treated with malonate. They can even be prepared from 
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the dianion of monoesters as well. 77 In other cases, esters of aroylacetic acid are first 
converted to diallylarnino derivatives.82• 78 
Another method is to condense acetophenones with diethylcarbonate in the 
presence of sodium hydride, which will eventually give the desired aroylacetate after 
sublimation, as shown in Scheme 1.21. 79 
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Scheme 1.21- Formation of alkoxymethylene derivatives 
There are different methods to prepare alkoxymethylene derivatives and convert 
them to N-substituted aminomethylene derivative in a subsequent step. One method is to 
use orthoformate with the ester of aroylacetic acid derivative, followed by treatment with 
amine (Scheme 1.22). 80 
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Scheme 1.22- Synthesis of N- substituted aminomethylene derivatives 
Another method IS to convert the corresponding ester to the 
dialkylaminomethylene derivative by dialkylformamide diacetal followed by treatment 
with an amine to give theN-substituted aminomethylene derivative (Scheme 1.23). SI - 82 
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Scheme1.23- N- Substituted 4- quinolone synthesis 
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1.8- DNA topoisomerases 
DNA topoisomerases are a group of omnipresent enzymes that are crucial for cell 
survival and proliferation in both prokaryotic and eukaryotic organisms. DNA 
supercoiling is controlled by topoisomerases. Some of these were originally named DNA 
relaxing enzymes, untwisting enzymes, or nicking-closing enzymes. These enzymes are 
found in all cell types that have been examined. Another group, the DNA gyrases, control 
the reverse action of changing relaxed closed-circular DNA to a superhelical form m 
bacteria. 83 
1.8.1- Family and subfamilies of DNA topoisomerases 
DNA topoisomerases are classified into two categories: type I and type II. For the 
type I enzymes, the DNA strands are transiently broken one at a time; while for the type 
II enzymes, both strands in a DNA double helix are transiently broken by the enzyme 
molecule which is in its dimeric form. Type lA topoisomerases include bacterial DNA-
topoisomerases I and III, yeast DNA topoisomerase Ill, Drosophila melanogaster DNA-
topoisomerases Ilia and III~ , mammalian DNA topoisomerases lila and III~. DNA type 
IB topoisomeases include eukaryotic DNA topoisomerase I, mammalian mitochondrial 
DNA topoisomerase I, and Pox virus topoisomerase. Type IIA topoisomerases include 
bacterial gyrase, DNA topoisomerase IV, Phage T4 DNA topoisomerase, yeast DNA-
topoisomerase II, Drosophila DNA topoisomerase II, man1malian DNA topoisomerases 
IIa and II~ ; and finally, Type II B topoisomerases include Sulfolobus shibatae DNA-
topoisomerase VI . 84 DNA gyrases are found in bacteria. 85 
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Topoisomerases work by cleaving one, or both strands of DNA, passmg a 
segment of DNA through the break, and resealing the gap. Relaxation of DNA is a 
thermodynamically favorable reaction, and indeed this enzyme does not require an input 
of energy. The enzyme does not simply hydrolyze a phosphodiester bond to form the 
break, but rather it remains attached to the 5'-phosphate group, forming a reactive 
intermediate. This bond can then be attacked by the 3'-hydroxy group to reform the 
phosphodiester bond, with no net change in energy except for the relaxation of one 
supercoil. Topoisomerases can catalyze the interconversion of other topological isomers 
of DNA. The level of DNA supercoiling in bacteria is most likely set by an equilibrium 
ofthe DNA supercoiling and DNA relaxing activities. 86 
A range of enzymes of this specific class completes the formation of tangled 
structures in single-stranded DNA. The topological interceptions of DNA demand the 
temporary breaking and recombination of DNA strands. Therefore, it is expected to see 
close structural homology with other molecules whose behaviors include the reversible 
and irreversible rupture of DNA and topoisomerases. Topoisomerase behavior has been 
established to be linked with the phage ~Xl74 cistron A protein. This protein cuts and 
reconnects at a specific site on the DNA molecule. It can catalyze transfer of an 
intermolecular strand at the same time as the recombination reaction. In conclusion, 
topoisomerases are ubiquitous enzymes that are implicated in metabolism of the DNA, 
through several pathways. 87 
DNA gyrase, converts the closed helix of DNA to negatively supercoiled DNA. 
The reaction requires A TP and Mg ++ and is stimulated by spermidine. This enzyme has 
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been purified from Escherichia coli cells and acts equally well on relaxed closed-circular 
colicin El, phage X, and simian virus 40 DNA. 88 
DNA gyrase is specifically inhibited by two classes of antibiotics, quinolone 
antibacterials and novobiocin. 89' 90 The intracellular target for the quinolone group of 
antibacterial agents is DNA gyrase. Interaction of quinolone antibacterials with a site 
containing DNA gyrase, results in relaxed closed-circular DNA, which results in 
inhibition of supercoiling. Quinolones will bind strongly to the complex of DNA and 
DNA gyrase. The complexation of quinolones and DNA gyrase is facilitated by ATP.91 
Novobiocin and cournermycin Al compete with ATP, thus they can destroy the 
energy coupling by preventing A TP binding. Regardless of the selective and competitive 
effect of novobiocin and coumermycin A 1 on A TP binding, there is no remarkable 
structural homology between these molecules and ATP. In fact, novobiocin has been 
shown to not affect any other A TP-requiring enzyme at very low concentrations. 
Nalidixic acid and ciprofloaxin have been shown to interfere with the cleavage and 
joining of the strands. 92 
1.8.2- Type II topoisornerases other than DNA gyrase 
Other Type II topoisomerases have been isolated from both prokaryotic and 
eukaryotic sources. These enzymes have been detected normally as A TP-dependent 
DNA-relaxing catalysts and consequently function by a type II mechanism. The first of 
this class was an enzyme which was purified from E . Coli. The purified protein has a 
molecular weight of approximately 50,000 Da, and requires ATP hydrolysis to 
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catalytically relax DNA. Novobiocin has no inhibitory activity for this category of 
enzymes.93 
The role of A TP in the activity of type II topoisomerases is not clear. So, it is suggested 
that they might have similar role as that of DNA gyrase . 
1.8.3- Biological activities of topoisomerases 
Topoisomerases catalyze reactions which are mostly ATP-dependant. DNA 
replication is also affected by DNA topoisomerases, for instance, elongation of 
replicating DNA chains, segregation of newly replicated chromosomes and initiation of 
the replication are all done by DNA topoisomerases. Initiation of replication is initiated 
by the closure of a short unmatched area of DNA. In plasmid-replication models, which 
are understood from studies on purified E. coli proteins, a negatively supercoiled shape is 
often needed for initiation. 94 
The necessity for a negatively supercoiled DNA model in vitro is indicative of 
involvement of DNA gyrase in the initiation of bacterial DNA replication. This feature 
requires DNA gyrase to dictate the direction of DNA segment passage through the 
enzyme-operated gate in one double-strand DNA. The mechanism by which the DNA 
segment is transported through the DNA gate is not known in detail. 95• 96 
In the replication of a closed circular DNA, the parental strands must be 
increasingly and completely unattached at the end of replication. Furthermore, a DNA 
. . l . d 101 top01somerase mvo vement IS man atory. 
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Topoisomerases are also involved in transcription as well. A DNA topoisomerase 
might be involved in continued translocation of the polymerase, and the efficient 
transcription of chromatin requires the presence of a DNA topoisomerase in the 
transcription complex. 97 From another biological point of view, the effect of 
topoisomerases on DNA recombination and chromosome condensation IS of high 
importance. 98 
In brief, topoisomerases are from a family of highly conserved essential enzymes, 
which exist in all scrutinized living prokaryotic and eukaryotic cells. They are essential 
for the control of DNA topology. These enzymes catalyze the inter-renovation of 
different topological forms of DNA through DNA breaking-passing-resealing processes. 
The universal nature of the enzyme makes it the target of choice for broad-spectrum 
antibacterial drugs and potent antitumor agents. 
1.9- Quinolones as antitumor agents 
In spite of their potential as attractive drug targets, the similarity between the 
topology of eukaryotic and prokaryotic topoisomerases causes difficulty in selectively 
targeting a specific enzyme. Fortunately, new tools such as molecular modeling and 
docking teclmiques have led to the discovery of novel gyrase inhibitors with broad-
spectrum antibacterial activity, and topisomerase I and II inhibitors as potential antitumor 
agents. One of the classes of compounds that have shown activity against prokaryotic 
topoisomerases (DNA gyrase) is quinolones. 99 
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Some groups of 2- and 4-quinolones substituted with a variety of different 
substituents demonstrated in vitro inhibition of human tumor cell lines. 4-Quinolone 
have been studied from different perspectives, such as their value as anticancer agents in 
both cell growth and cell migration.10° From an illustrative point of view, the expansion 
of malignancy in tissue happens in the following steps. Some genomic mutations increase 
cell proliferation and decrease cell death, causing disruption in cell cycle kinetics, which 
eventually end up having uncontrolled growth of a transformed cell population. Later on, 
the transformed cells accumulate and form a cancerous tissue. Some of these cells might 
later migrate from the tumor bulk and colonize new tissues, a process which is called 
metastasis. The migrating cells use lymphatic vessels or blood as major routes of 
migration. One of the major classes of chemotherapeutic agents used clinically against 
cancers are drugs that target processes including nucleoside synthesis and DNA 
replication, the processes that control cell proliferation. The discovery of apoptosis in the 
early 1970s showed that a low rate of cell death has a higher impact than high rate of cell 
proliferation, which means that fast growing tumors are not always the ones with higher 
proliferation rate. 101 
A variety of anticancer agents target topoisomerases, the enzymes that play an 
essential role in DNA duplication. 102 Some examples are drugs like doxorubicin and 
etoposide which are already in the market and are used as inhibitors of topoisomerase 
II.I03 
The clinically approved anticancer agents often target the cell kinetics and cell 
proliferation rather than cell death. There are other options for cancer treatment such as 
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immunotherapy and gene therapy. The reason for the shift toward development of other 
treatment options is because the majority of drugs that are used clinically have high 
toxicity which limit their clinical use. Furthermore, these drugs must be combined with 
other drugs in multi-drug regimens in order to have significant treatment outcome. 105 
A variety of 2-arylquinolones, with the goal of developing nontoxic anticancer 
agents with antimigratory mode of action that can complement the action of the already 
used anticancers, have been synthesized and reported to exhibit significant efficacy in 
animal models. 104 
1.10- Structure-based drug design 
The field of structure-based drug design is a rapidly growing area in which many 
successes have been reported in recent years. The exploration of molecular and structural 
data has provided many new targets and opportunities for future drug I ad discovery. 
During the years of 1985 to early 1990, the first publications and the first attempts made 
the field of structure-based drug design interesting for researchers. Subsequently, this has 
become an important tool in research laboratories and institutes. 105 
The completion of the human genome project and the advances in information 
technology have made structure-based drug design more of a favorable project to be 
undertaken. By development of bioinformatics better drug targets were identified. Genes 
of those targets can be cloned and are available in pure forms. The cloning process is 
quick, and the protein is expressed and purified to homogeneity. Advances in nuclear 
magnetic resonance (NMR) spectroscopy, X-ray crystallography, and high throughput 
screening of the targets, as well as faster and more advanced computers, have made 
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structure-based drug design of high importance for the discovery of lead compounds. 106-
107 
The procedure of structure-based drug design is a stepwise process and usually 
proceeds through multiple steps before the lead compound can enter the clinical trial 
stage. The first step includes the comparison of the available natural or synthetic 
molecules with the preliminary molecule, then to make a set of compounds and modify 
them with respect to their minimum energy levels and other factors involved in their 
modification. 
Using computer algoritlm1s, compounds or fragments of compounds from a 
database, X-ray crystallography, NMR, or homology modeling of former active or emi-
active compounds can help in selecting the best target molecules among the designed 
molecules. These compounds are scored and ranked based on various factors, such as 
their electrostatic and steric interactions with the active site. Later on, a final match of the 
proposed lead compound with the target in a complex consisting of the active site and the 
designed molecule will be evaluated. Further steps of optimization are all done on the 
premise of the first evaluation of the drug in the complex. Choosing a target is based on 
the type of the disease and biological and pharmacological assessment of the active site. 
Cancer targets can be difficult because the targets are usually somatic cell mutants of 
proteins that control essential cellular processes. The consequences of the malfunctioned 
proteins are loss of cellular control as well as cell injury. The most challenging pru1 of 
designing anticancer drugs is finding lead compounds which ru·e normally mall 
molecules with the potential of disrupting the dysfunctional chain. 108 
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There are three major criteria m the structure-activity-based molecular design 
strategy. One is pharmacophore mapping, another is a three-dimensional search of both 
the lead compound and the target as well as molecular design, and the third is the 
evaluation of the three-dimensional quantitative structure-activity relationships. All these 
information is used to convert a two-dimensional structure of a bioactive molecule into 
its three-dimensional features. 109 
1.10.1- Pbarmacophore identification 
A pharmacophore is a three-dimensional map of certain functional groups and 
ligands that are necessary to exhibit biological activity. The biological properties of 
pharrnacophores are common to all active configurations which show the desired activity. 
The idea of pharmacophore identification is to establish the bioactive conformations of 
the ligands and how to apply the template for drug design. From information like 
structure-activity relationships, a pharmacophore would first be proposed. The chemical 
nature of the functional groups that are assigned for the pharrnacophore are needed for its 
in vitro and in vivo evaluation. Later on, by modification and changes in functional group 
there would be other requirements that are essential to be considered such as, efficacy 
and suitable bioactivity of the pharmacophore. The molecules are compared by their 
overlay based on the required functional groups and their match with the binding ites. 
The volume and the space that is occupied by the pharmacophore as overlaid with the 
suggested lead compound(s), bring about the idea of the regions in area that can be filled 
by any newly designed active ligand. 
43 
1.10.2- Three-dimensional searching 
Three-dimensional searching recognizes existing molecules, or natural products 
that counterpart the proposal of the three-dimensional requirements for activity in vivo 
and in vitro. Three-dimensional searching facilitates other necessary featuressuch as 
recognition of potential lead molecules based on their three-dimensional capacities. 
Furthermore, many of the existing programs use three-dimensional searching to compare 
the designed molecule with already synthesized and available compounds. Obviously, the 
lead compound wi II be chosen on the basis of its ease of synthesis and on its favorable 
physicochemical properties. For example, molecular modelers usually are questioned as 
to whether the program would build the molecule based on already existing bioactive 
compounds, such as building similar antibacterial models from natural antibacterial 
structures. The proposed compounds will be tested for a pharmacophore model. Three-
dimensional searching is parallel to three-dimensional QSAR, because it can be 
employed to propose a set of compounds and leads for the three-dimensional QSAR 
analysis. Furthermore, three-dimensional QSAR will finally be used to rank the 
suggested compounds for synthesis if there are readily available chemical sources such as 
110- 11 3 
natural compounds Three-dimensional searches are mainly subdivided into 
geometric, steric, and similarity searches. 
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1.10.3- Geometric searches 
The idea of geometric searches is to look for the intramolecular relationships 
between geometric objects, such as points, lines, and planes that can be calculated from a 
b . bl 11 4 structure y a stuta e computer program. 
1.10.4- Similarity searching 
Similarity searching is concerned with how comparable a molecule m the 
database is with the three-dimensional characteristics of a known molecule. 121 
1.10.5- Steric Searching 
In steric searching, the program evaluates the candidate molecule ' s shape for 
filling into the specific space that it should fill. The deduction of a steric search is based 
on different available enantiomers of a molecule, their orientation and selectivity. 121 
1.10.6- Three-dimensional quantitative structure-activity relationships 
Biologically-active compounds interact with their biological targets to start or 
maintain specific molecular mechanisms or functions, such as activation of an enzymatic 
cascade, or opening of an ion channel, which eventually leads to a specific biological 
action. Quantitative structure-activity relationships (QSAR) relate the biological response 
with molecular specificities of the molecule or compounds of interest. Because the 
biological feedback depends on the lead compound's potency and its concentration at the 
site of action, these aspects should be taken into consideration by QSAR models. 11 5 
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In three-dimensional QSAR, criteria such as surface, volume or electrostatic 
potential are calculated from the spatial structure of the molecule. 11 6 In two-dimensional 
QSAR, molecular depictions of various levels are connected with the biological activity. 
Two-dimensional descriptors are topological features and information about how the 
atoms are connected with each other in the molecule. One-dimensional descriptors 
include variables that confirm the presence or absence of an atom or a group in the 
molecule. 11 7 
Among the foremost three-dimensional -QSAR methods is CoMF A (Comparative 
Molecular Field Analysis): 118 "The superimposed molecules are located in a three-
dimensional grid database and at each grid point a steric and an electrostatic interaction 
energy with a probe is calculated. The molecular fields obtained in this way are then 
correlated with the biological activity by partial least-squares (PLS) analysis." 122 The 
critical step in CoMF A (and generally related methods) is to locate the position of the 
designed structure. The steric contributions are represented by a binary code and the 
electronic contributions are attained by evaluating the molecular electrostatic prospective 
at the grid points, rather than the calculated interaction energy with a probe. In 
calculating the effect of shape and hindrance, selection of molecules which contain the 
desired characteristic is more predictable, and the accuracy and predictability value in 
comparison with one-dimensional-QSAR and/or two-dimensional-QSAR is much higher 
and more advanced. 
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2- Materials and instruments 
2.1- Chemical reagents 
3-Fluorphenylisothiocyanate (catalogue number F 14351- 1 00) with the purity of 
(97%), 3-butyn-1-ol (catalogue number 130850-50) with the purity of (97%), 2-
fluorobenzoic acid (catalogue number 412244-250) with the purity of (97%), 
cyclopropylmethanol (catalogue number 482099-25ML ) with the purity of(+ 99.5%), 
cyclobutylmethanol (catalogue number 187917-50) with the purity of (99%) 2-
fluorobenzyl alcohol (catalogue number 162515-50) with the purity of (98%), 0-ribose 
(catalogue number R1757-100) with the purity of (98%),were purchased from igma-
Aldrich Inc.,3050 Spruce street, St.Louis, MO 63103 USA. 4-fluorobenzylalcohol 
(catalogue number F740-7- 50) with the purity of (97%), 3-fluorobenzylalcohol 
(catalogue number 16250-7-50) with the purity of (98%), 2,4-difluorobenzoylchloride 
(catalogue number 265292-250) with the purity of (98%), mono-ethyl malonate 
(catalogue number 445088-50) with the purity of (95%), acetyl chloride (catalogue 
number 11418-9-250) with the purity of (98%), 4-fluorophenol (catalogue number 
Fl 3207-250) with the purity of(99%), benzyl isothiocyanate (catalogue number 252492-
250) with the purity of (98%), 2' ,4'- difluoroacetophenone (catalogue number 26425-
3,100) with the purity of (98%), 2-butyn-1-ol (catalogue number 244341-50) with the 
purity of (98%), benzoyl chloride (catalogue number B 1269-5-25ML) with the purity of 
(99%), benzylan1ine (catalogue number 185701- 1000) with the purity of (99%), 1-
heptanol (catalogue number H2805-1000) with the purity of (98%),ethyl 2-
fluorobenzoylacetate (catalogue number 225134-1 00), technical grade 2-chloro-2' ,4 ' -
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difluoro-acetophenone (catalogue number 272507-25G) with the purity of (98%), !-
naphthyl methanol (catalogue number I84284-IOG) with the purity of (98%), 2,4-
difluorobenzoic acid (catalogue number 264296-25G) with the purity of (98%), 2-
naphthyl methanol (catalogue number 187313-5G) with the purity of (99%), cesium 
carbonate (catalogue number 202126-25G) with the purity of (99.9%), magnesium 
ethoxide (catalogue number 291846-1 OOG) with the purity of (98% ), diethyl 
carbonate(catalogue number 5I7I35-IOOML) with the purity of(+99%), ally alcohol 
(catalogue number 240532-IOOML) with the purity of (+99%), were purchased from 
Aldrich Chern. Co, Milw. WI 53201. USA. Chromatographic silicagel [200-425 Mesh] 
was purchased from Fisher Chemicals [Fisher Scientific] , Fair Lawn New Jersey, USA. 
2.2- Instruments 
2.2.1- Nuclear magnetic resonance 
1H- and 13C-NMR spectra were recorded usmg a Bruker Avance 500 
spectrometer, equipped with inverse detection and auto tune, capable of doing both one-
dimensional and two-dimensional NMR analyses. Data analysis was performed on 
networked PCs operating software using Acorn NMR. 
2.2.2- Liquid chromatography- Mass spectrometry (LC I MS) 
Molecular weight data were gathered by utilizing a Hewlett Packard II 00 
LC/MS system equipped with degasser, binary pump, photodiode array detector and 
electrospray ionization mass spectrometry (ESI-MS) or atmospheric pressure chemical 
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ionization mass spectrometry (APCI-MS), using LC/MSD ChemStation, rev. A. 08.03 
(874) software. Tllis equipment is capable of determining a mass range of rnlz 50-3000 
with a mass accuracy of 0.1 amu. The HPLC system and the ChemStation software were 
from Agilent Technologies Deutscland GmbH, Waldbronn, Germany. The MSD 
component was from Agilent Teclmologies Inc., PaloAlto, CA, U.S.A. 
2.2.3- Gas chromatography- Mass spectrometry (GC I MS) 
The mass data of smaller molecules with less heat sensitivity were collected by 
using HP 5970 GC/MSD. The MS detector operated with positive EI mode. The mass 
range available was rn/z 50-800. 
2.3- Methods and results 
Quinolin-4(1H) one-3-carboxylic acid derivatives (quinolones) have been utilized 
smce the early 1980s as potential antimicrobial agents that target bacterial Topo-II 
isomerase (gyrase) and Topo-IV isomerase. Recently, novel tricyclic and tetracyclic 
quinolones have been reported as agents that selectively target human Topoisomerases I 
and II, and exhibit significant anticancer activity. 11 9 In a literature search for novel 
quinolones with potential anticancer activity, a joint patent by Japanese pharmaceutical 
companies, Kyorin/Kyowa-Hakko, describing thiazoloquinolone carboxylic acids with 
impressive anticancer activities, compound A, 120 attracted our attention. The clinical 
candidate compound had exhibited favorable drug-like properties in different animal 
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models in preclinical studies. The structure of the candidate compound is depicted m 
Figure 2.1. 
OH 
Figure 2.1- Structure of compound A 
Compound A, like other quinolone carboxylic acid derivatives, is presumed to 
interact with topoisomerases via its P-keto acid functional group (the free carboxylic acid 
and the keto group) and chelate with the Mg2+ ion to inhibit the enzyme. Considering this 
mode of action, we hypothesized that a quinolone with a P-diketo functionality may be 
able to mimic the action of P-ketoester functionality, thus potentially providing the same 
level of chemical interaction with the Mg2+ ion. Also, due to the absence of free 
carboxylic acid functionality, the target quinolone may cause less gastric damage if the 
drug is used by oral route. 
In order to design P-diketo analogues of compound A, the Daneshtalab group 
attempted a structure-based design technique using the Alchemy-3 TM molecular modeling 
program. The computational chemistry was performed by Dr. Alan Cameron on a Silicon 
Graphic-Octane 2 computer system at the SynPhar Laboratories Inc., in Edmonton, 
Alberta, Canada. In this respect, the structure of compound A was drawn and its most 
sterically/energetically optimum configuration was determined using Molecular 
Mechanics Optimization (MMO) and Molecular Dynamic Options methods. Using this 
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structure as a reference, attempts were made to identify linear tricyclic quinolones with ~-
diketo components that match the angular feature of compound A. In this respect, 
compound B, 9-benzyl-7-fluoro-3-hydroxyisothiazolo[4,5-b ]quinoline--4(9H)-one (6a) 
(Figure 2.2), at its optimized steric/energetic configuration, was found to have the best 
match with a perfect 3-point overlay with compound A (Figure 2.3). 
0 OH 
F N 
\) 
Figure 2.2- Structure of compound B (6a) 
Figure 2.3- Two different overlays of compound A (dotted lines) and compound B (solid 
lines) 
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The objective of this research was to design appropriate synthetic methodologies 
for compound B (6a) and its N-substituted analogues in order to evaluate their potential 
as novel mechanism-based anticancer agents. 
The following retrosynthetic pathway was first hypothesized for the synthesis of 
compound B and its N 1-substituted analogues, as depicted in Scheme 2.1. Namely, 
starting from 3-fluorobenzylisothiocyanate, diethyl malonate, and an appropriate alkyl 
halide, compound 2 was expected to form, further Gould-Jacob type ring closure of 
which would result in the formation of compound 3. Benzylation of this compound is 
expected to give rise to compound 4 which upon S-dealkyation would afford compound 
5. The final step in this procedure was formation of the third ring via reaction of 
compound 5 with hydroxyla.mine-0-sulfate to obtain the desired compound 6a. 
0 
==> 
OC2H5 
F N F N N I I I 
CH2Ph CH2Ph CH2Ph 
6a (B) 5 4 
OH 
+ 
< COzCzHs 
+ C02C2H5 
F 
3 2 X-R1 
Scheme 2.1- Retrosynthetic pathways hypothesized for the synthesis of 
compound B (6a) 
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The stepwise syntheses of compound B and its N1-substituted analogues were 
attempted based on the above hypothetical pathways, as described in the following 
sections. 
1 2 
2 R1 
a -CH20CH2CH3 
b -CH20CH3 
c -CH3 
Scheme 2.2- Synthesis of the intermediates 2 a-c 
2.3.1- Diethyl [(3-Fiuoroanilino)[(ethoxymethyl)thio]methylene]rnalonate (2a) 
To a suspension of 60% NaH (1.44 g, 36 mmol) in anhydrous THF at 0 °C, diethyl 
malonate (4.8 g, 30 mmol) was added dropwise. The reaction mixture was stirred for 30 
minutes at the same temperature. 3-Fluorophenylisothiocyanate (1) (4.59 g, 30 mmol) 
was added dropwise to the reaction mixture and stirred for another 30 minutes. 
Chloromethyl ethyl ether (2.85 g, 30 mmol) was then added dropwise to the reaction 
mixture at the same temperature and stirred for 1 hour at room temperature. 
The reaction mixture was concentrated under reduced pressure, water was added 
to the reaction mixture and the crude product was extracted with ethyl acetate. The ethyl 
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acetate solution was washed with an aqueous saturated solution of sodium chloride, dried 
over sodium sulfate, filtered and the solvent evaporated under reduced pressure. A pale 
yellow oil (1 0.6 g, 28.5mmol) was obtained in 95% yield. 
1H NMR (CDCb): 8 1.097-1.098 (3H, t, J=7.5 Hz), 1.258-1.298 ( 6H, t, J=7. 5 Hz), 
3.362-3.446 (2H, q, J =6.5 Hz) , 4.189-4.251 (4H, m), 4.644 (2H, s), 6.834-6.867 (lH, dd, 
J=2.5 Hz, J =8.5 Hz), 7.058-7.102 (2H, m), 7.246-7.291 (lH, dd, J =3.0 Hz, J =7. 5 Hz). 
Molecular formula: C 17H22FN05S; Exact Mass Found: 371. 12, Calculated: 371.42. 
2.3.1.1- Diethyl [(3-Fluoroanilino)((methoxymethyl)thio]methylene]malonate (2b) 
Compound 2b was synthesized in 90% yield (9.7 g, 27 mmol). , as a pale yellow 
oil, by the same method as described above and employing chloromethylmethyl ether 
(2.4 g, 30 mmol) instead of chloromethylethyl ether. 
1H NMR (CDCb): 8 1.980-1.350 (6H, m), 3.212 (3H, s), 4 .280-4.308 (4H, q, J=7.0 Hz), 
4.918 (2H, s), 6.706-6.831(1H, dd, J=3.5 Hz, J =8. 0 Hz), 6.960-6.980 (2H, m), 7.137-
7.212 (lH, dd, J=2.5 Hz, J =7. 5 Hz). 
Molecular Formula: C 16H20FN05S; Exact Mass Found: 357.10, Calculated: 357.40. 
2.3.1.2- Diethyl [(3-Fiuoroanilino)[(methyl)thio]methylene]malonate (2c) 
This compound was produced using the same method as described for 2a,b and 
employing methyl iodide( 4.26 g, 30 mmol) instead of chloromethyl ethers. The product 
was a yellow oil in 98% yield (9.68g, 29.5 mmol) . 
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1H NMR (CDCl3): o 1.230-1.273 (6H, m), 2.0 17 (3H, s), 4.345-4.355(4H, m), 6.846-
6.885 (lH, dd, J =3.0 Hz, J=8.5 Hz), 7.106-6.144 (2H, m), 7.272-7.3 12 (1H, dd, J=2.6 
Hz, J=7. 6Hz). 
Molecular Formula: C15H 1sFN04S; Exact Mass Found: 327.09, Calculated: 327.37. 
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2.3.2- Ethyl 7-Fiuoro-4-hydroxy-2-[(ethoxymethyl)thio]-3-quinoline carboxylate 
(3a) 
Compound 2a (1 0.6 g, 28.5 rnmol) without further purification was heated under 
vacuum (0.6 mmHg) at 170-175 ° C for I 0 minutes. After cooling, the residue was 
crystallized from a mixture of ethyl acetate and hexane to yield yellow crystals (7 .41 g, 
22.8 mmol) (mp: 145-1 50 °C, 80% yield). 
1H NMR (CDCh): o 1.219-1.247 (3H, t, J =7. 0 Hz), 1.525-1.552 (3H, t, J=6.5 Hz), 3.670-
3.714 (2H, q, J=7. 5 Hz), 4.530-4.575 (2H, q, J=7. 5 Hz), 5.547 (2H, s), 7.1 68-7.208 (IH, 
dd, J= 2.5 Hz, J=9.0 Hz), 7.435-7.459 (lH, dd, J=3.0 Hz, J= 10.0 Hz), 8.216-8.247 (lH, 
dd, J=7. 0 Hz, J=.09 Hz). 
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13C NMR (CDCl3): o 14.2, 15.0, 57.8, 63 .1 , 72.9, 103.0, 112.2, 112.3, 115.2, 115.4, 
126.4, 126.5, 159.8, 168.8, 171.0. 
Molecular Formula: C 15H 16FN0 4S; Exact Mass Found: 325.08, Calculated: 325.36. 
2.3.2.1- Ethyl 7-Fluoro-4-hydroxy-2-[(methoxymethyl)thio]-3-quinoline carboxylate 
(3b) 
This compound was synthesized using the same procedure as described for 3a to 
yield (6.5 g, 21 nunol) colorless crystals with melting point of (140-145 °C) and 70 % 
yield. 
1H NMR (CDCb): o 1.529-1.558 (3H, t, J=7. 5 Hz), 3.464 (3H, s), 4.540-4.591 (2H, q, 
J=7. 0 Hz), 5.498 (2H, s), 7.171-7.260 (IH, dd, J= 3.6 Hz, J=9. 0 Hz), 7.450-7.70 (1 H, dd, 
J=4.0 Hz, J= 10.0 Hz) , 8.217-8.247 (IH, dd, J =6.0 Hz, J= 10.0 Hz). 
'
3c NMR (CDCh): 14.2, 57.8, 63.1, 72.9, 103.0, 11 2.2, 112.3 , 11s.2, 115.4, 126.4, 126.5, 
159.8, 168.8, 171.0 
Molecular Formula: C 14H 14FN04S; Exact Mass Found: 311.06, Calculated: 311.33. 
2.3.2.2- Ethyl 7-Fiuoro-4-hydroxy-2-(methylthio)-3-quinoline carboxylate (3c) 
Compound 3c was produced using the same method as described for 3a,b to 
produce 7.58 g (27 mmol, 90%) of a yellow solid with a melting point of 120-125 °C. 
1H NMR (CDCh): o 1.520-1.552 (3H, t, J=8.0 Hz), 3.585 (3H, s), 4.528-4.571 (2H, q, 
J=8.0 Hz), 7.13 1-7.177 (IH, dd, J= 3.8 Hz, J=9.0 Hz), 7.420-7.440 (1H, dd, J=2.8 Hz, 
J= 11.0 Hz), 8.199-8.230 (IH, dd, J=5.0 Hz, J= 11.0 Hz). 
56 
13C NMR (CDCb): 13.6, 15.1 , 62.7, 103.0, 112.2, 11 2.3, 115.2, 115.4, 126.4, 126.5, 
159.8, 168.8, 171.0 
Molecular Formula, C 13H 12FN03S; Exact Mass Found: 281.05, Calculated: 281.30. 
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2.3.3- Ethyl 1-Benzyl-7 -fluoro-2-[ ( ethoxymethyl)thio ]-quinolin-4(1 H)-one-3-
carboxylate (4a) 
To a solution of 3a (6.5 g,20 mmol), triphenylphosphine (6.29g,24 mmol) and 
benzyl alcohol (2.16g,20 mmol) in THF, diisopropyl azodicarboxylate (DIAD) (4.85g,24 
mmol) was added dropwise. The reaction mixture was stirred for six hours. After the 
removal of the solvent under reduced pressure, anhydrous diethyl ether was added and 
allowed to stand for 5 hours, then filtered. The diethyl ether was evaporated under 
reduced pressure and the oily residue was purified by silica gel column chromatography 
(20: 1 hexane: ethyl acetate) to yield a pale yellow oil (7.47 g, 18 mmol, 90 %). 
1H NMR (CDCb): 8 1.213-1.241 (3H, t, 1=7. 0 Hz), 1.407-1.436 (3H, t, 1=7. 0 Hz), 3.656-
3.699 (2H, q, 1=7, 5 Hz) , 4.445-4.487 (2H, q, 1=7. 0 Hz), 5.234 (2H, s), 5.636 (2H, s), 
7.160-7.199( lH, dt, 1=2.0 Hz, 1=9.5 Hz), 7.384-7.450 (5H, m), 7.554-7.580 (lH, dd, 
1=2.0 Hz, 1=9.5 Hz), 7.999-8.029 (1 H, dd, J=6.0 Hz, J=9.5 Hz). 
13C NMR (CDCb): 14.2, 15.1 , 58.6, 62.6, 65.4, 71.7, 112.3, 112 .5, 115.9, 116.1, 125.4, 
125 .5, 126.4, 128.8, 128.9, 136.0, 150.3, 157.9, 160.4, 163.5, 165.5, 166.2. 
Molecular Formula: C22H22FN04S; Exact Mass Found: 415 .13, Calculated: 415.48. 
2.3.3.1- Ethyi1-Benzyl-7-fluoro-2- [(methoxymethyl)thio]-quinolin-4(11/)-one-3-
carboxylate ( 4b) 
This compound was prepared with the same procedure as described in section 
2.3.3 , employing (6.22 g, 20 mmol) of compound 3b and benzyl alcohol (2.1 6 g, 20 
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mmol). Ratios of triphenylphosphine and DIAD were the same as for 4a. The product 
with the yield of 90% was a colorless oil (7 .2 g, 18 mmol). 
I H NMR (CDCb): o 1.407-1.436 (3H, t, 1= 7. 5 Hz), 3.444 (3H, s), 4.383-4.425 (2H, q, 
1=7. 8 Hz), 5.172 (2H, s), 5.636 (2H, s), 7.120-7.159 (lH, dt, 1=2.9 Hz, J =9.8 Hz), 7.364-
7.421 (5H, m) 7.602-7.645 (IH, dd, 1=2.6 Hz, J=9.8 Hz), 7.802-7.819 (lH, dd, 1=7.0 
Hz, J=ll.O Hz). 
13C NMR (CDCb): 14.2, 58.6, 63.0, 65.4, 72.7, 112.3, 112.5, 115.9, 116.1 , 125.4, 125.5, 
126.4, 128.8, 128.9, 136.0, 150.3, 157.9, 160.4, 163.5, 165.5, 166.2. 
Molecular Formula: C21H2oFN04S; Exact Mass Found: 401.11, Calculated: 401.45. 
2.3.3.2- Ethyll-(4-Fiuorobenzyl)7-fluoro-2-[(ethoxymethyl)thio]-quinolin-4(JH)-
one-3-carboxylate (4c) 
Compound 4c was synthesized utilizing the same technique as described in 
section 2.3.3, using compound 3a (6.5 g, 20 mmol) and 4-fluorobenzyl alcohol (2.52 g, 
20 mmol). The product with the yield of 98% was a colorless oil (8.5 g, 19.5 mmol). 
Ratios of triphenylphosphine and DIAD were the same as used for 4a. 
1H NMR (CDCb): o 1.113-1.2 11 (3H, t, 1= 7. 5 Hz), 1.417-1.426 (3H, t, J= 7.5 Hz), 
3.655-3.699 (2H, q, J=7. 5 Hz), 4.455-4.488 (2H, q, 1=7.5 Hz), 5.254 (2H, s), 5.686 (2H, 
s), 7.083-7.093(2H, dt, J =5.0 Hz, J=9.5 Hz), 7. 148-7.187 (lH, dt, 1=6.0 Hz, J=ll .O Hz) , 
7.404-7.428 (2H, dd, J=8.0 Hz, J=ll.O Hz),7.540- 7.563 (lH, dd, 1=9.0 Hz, 1=14.0 Hz), 
7.949-7.977 (lH, dd, J=9.0 Hz, 1=12. 0 Hz). 
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13C NMR (CDCl3): & 14.2, 15.0, 57.8, 62.5, 65.4, 72.8, 112.3, 112.5, 114.9, 115, 125.4, 
125.5, 130.2, 131.9, 131.8, 133.1 , 150.8, 159.8, 160.1, 163 .5, 165.5, 166.2. 
Molecular Formula: C22H2 1F2N04S; Exact Mass Found: 433.12 , Calculated: 433.47. 
2.3.3.3- Ethyll-(3-Fiuorobenzyl)7-fluoro-2- [ethoxy)methyl thio)-quinolin-4(1H)-
one-3-carboxylate ( 4d) 
Treatment of 3a (6.5 g, 20 mmol) with (2.5 g, 20 mmol) of 3-fluorobenzyl 
alcohol using the same ratios of triphenylphosphine and DIAD, as described with the 
formation of compound 4a, yielded (8.4 g, 19 mmol) of compound 4d as a pale yellow 
oil (96%). 
1H NMR (CDCh): & 1.213-1.291 (3H, t, J= 7.4 Hz), 1.411-1.424 (3H, t, J = 7.5 Hz), 
3.652-3 .693 (2H, q, J =7. 5 Hz), 4.405-4.477 (2H, q, J =7. 5 Hz), 5.229 (2H, s), 5.624 (2H, 
s), 7.040-7.073 (lH, t, J =J2.0 Hz ), 7.176-7.242 (3H, m), 7.342-7.371 (lH, dd, J =7.5 Hz, 
J=IO.O Hz), 7.551-7.572 (1H, dd, J=8.5 Hz, J =J3.0 Hz) , 7.978-7.994 (lH, dd, J =8.5 Hz, 
J=l2.0 Hz). 
13C NMR (CDC13): 14.2, 15.1, 58.6, 62.6, 65.4, 72.9, 11 2.4, 112.5, 115.8, 116.0, 125.4, 
125.5, 126.4, 128.8, 128.9, 136.1 , 150.2, 157.9, 160.3, 163.5, 165.5, 166.3. 
Molecular Formula: C22H21F2N04S; Exact Mass Found: 433 .12, Calculated: 433.47 
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2.3.3.4- Ethyll-(2-Fluorobenzyl)-7-fluoro-2-[ethoxymethyl)thio]-quinolin-4(1H)-
one-3-carboxylate ( 4e) 
Compound 4e was prepared utilizing the same technique as described in section 
2.3.3, using compound 3a (6.5 g, 20 mmol) and 2-fluorobenzyl alcohol (2.52 g, 20 
mmol). The product was a pale yellow oil (8.5 g, 19.6 mmol) with the yield of 98%. 
Ratios of triphenylphosphine and DIAD were the same as for 4a. 
1H NMR (CDCb): 8 1.223-1.281 (3H, t, 1= 7 5Hz), 1.321-1.423 (3H, t, 1= 7 5Hz), 
3.642-3.673 (2H, q, 1=7 5 Hz), 4.415-4.467 (2H, q, 1=7 5 Hz), 5.239 (2H, s), 5.623 (2H, 
s), 7.140-7.153 ( 1H, t, 1=12.0 Hz), 7.166-7.262 (1H, dd, 1=8.0 Hz, 1=11.0 Hz), 7.352-
7.372 (2H, m),7.551- 7.572 (lH, dd, 1=8.5 Hz, 1=13.0 Hz), 7.668-7.776 (lH, m), 7.978-
7.994 (1 H, dd, 1=8. 0 Hz, 1= 13.0 Hz). 
13C NMR (CDCb): 14.1 , 15.0, 62.5 , 65.4, 70.8, 71.7, 112.3 , 112.5, 115.9, 116.1, 125.3, 
125.4, 126.4, 130.8, 130.9, 136.0, 150.3, 157.9, 160.4, 163.5, 165.5, 165.9. 
Molecular Formula: C22H21F2N04S ; Exact Mass Found: 433.12 , Calculated: 433.47. 
2.3.3.5- Ethyl 1-( 4-Methoxybenzyl)-7-fluoro-2-[( ethoxymethyl)thio )-quinolin-4(1 H)-
one-3-carboxylate ( 4f) 
This compound was synthesized according to the procedure described for 
preparation of 4a by employment of (2.76 g, 20 mmol) of 4-methoxybenzyl alcohol, to 
form 4f as a pale yellow oil with 95% yield (8.45, 19.5 mmol) . 
1H NMR (CDCb): 8 1376-1.401 (3H, t, 1= 7 5Hz), 1.457-1.666 (3H, t, 1= 7 6Hz), 3.545-
3.669 (2H, q, 1=7 5 Hz), 3.811 (3H, s), 4.412-4.488 (2H, q, 1=7 6Hz), 5.270 (2H, s) 
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5.677 (2H, s), 6.918-7.930 (2H, dt, J=6.0 Hz, J =9.0 Hz), 7.157-7.179 (lH, dt, J =5.5Hz, 
J=l0.5 Hz), 7.304-7.417 (2H, dd, J =7. 5 Hz, J =JO.O Hz),7.531-7.553 (lH, dd, J =8.5Hz, 
J= 13.0 Hz), 7.961-7.989 (1 H, dd, J=9.0 Hz, J=l2. 0 Hz). 
13C NMR (CDCb): 14.3, 15.1, 56.0, 58.6, 62.6, 65.4, 71.7, 11 2.3, 112.5, 115.9, 116.1 , 
125.4, 125.5, 128.8, 128.9, 136.0, 150.3, 157.9, 158.0, 160.4, 163.5, 165.4, 166.3. 
Molecular Formula: C23H24FN05S; Exact Mass Found: 445.14, Calculated: 445.50. 
2.3.3.6- Ethyl 1-Ethyl-7-fluoro-2-[( ethoxymethyl)thio]-quinolin-4(1H)-one-3-
carboxylate. ( 4g) 
Treatment of (3a) with ethyl alcohol (0.92 g, 20 mmol), using the same procedure 
as described for compound 4a, afforded compound 4g as a colorless oil (6.7 g, 18 mmol, 
95 %). 
1H NMR (CDCh): 8 1.220- 1.267 (6H, m), 1.520-1.549 (3H, t, J = 7.5 Hz), 3.685-3 .699 
(2H, q, J=7. 6 Hz), 4.4538-4.552 (2H, q, J =7.5 Hz), 5.212-5.263 (2H, q, J =7. 6 Hz), 5.536 
(2H, s), 7.036-7.073( 1H, dt, J=3.0 Hz, J =8.5 Hz), 7.416-7.445 (1H, dd, J =2.5 Hz, 1=9.0 
Hz), 8.194-8.224 (1 H, dd, 1=7. 0 Hz, J=B. 5Hz). 
Molecular Formula: C 17H20FN04S; Exact Mass Found: 353.11 , Calculated: 353.41. 
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2.3.3. 7- Ethyl 1-(Propyl)7-fluoro-2-[ ethoxymethyl)thio ]-quinolin-4{1 H)-one-3-
carboxylate (4h) 
This compound was synthesized in 90% yield as a pale yellow oil (6.6 g, 18 
mmol) employing the same procedure as described for compound 4a, using 1-propanol 
(1.2 g, 20 mmol). 
1H NMR (CDCi)): 8 0.999-1.034 (3H, m), 1.210-1.247 (6H, m), 1.519-1.539 (3H, t, 
J=7. 3 Hz), 3.685-3.699 (2H, q, J =7.4Hz), 4.464-4.653 (2H, q, J=7. 5 Hz), 5. 11 3-5.272 
(2H, q, J =7. 5 Hz), 5.544 (2H, s), 7.024-7.054 ( 1 H, dt, J=2.5Hz, J=7.5 Hz), 7.326-7.345 
(1H, dd, J=2.4 Hz, J=8.0 Hz), 8.184-8.214 (1H, dd, J =7. 0 Hz, J=8. 0 Hz). 
Molecular Formula: C1sH22FN04S; Exact Mass Found: 367.13, Calculated: 367.44. 
2.3.3.8- Ethyl 1-(Butyl)-7-fluoro-2-[ ( ethoxymethyl)thio ]-quinolin-4{1H}-one-3-
carboxylate ( 4i) 
Compound 4i (6.48 g, 17 mmol) was prepared as a yellow oil in 85% yield 
employing the same procedure as described for compound 4a, using 1-butanol ( 1.48 g, 
20 mmol). 
1H NMR (CDCi]): 8 0.987-1.040 (3H, m), 1.210-1.348 (7H, m), 1.629-1.639 7(3H, t, 
J=7.5 Hz) 3.675-3 .689 (2H, q, J =7. -l Hz), 4.453-4.673 (2H, q, J=7. 5 Hz) 5.013-5.163 
(2H, q, J=7. 6 Hz), 5.532 (2H, s), 7.114-7.144( 1H, dt, J=2.0 Hz, J=7.0 Hz), 7.436-7.448 
( lH, dd, J=2.6 Hz, J=7. 5 Hz), 8.104-8.103 (lH, dd, J=7. 5 Hz, J=9.0 Hz). 
13C NMR (CDCi]): 13.3, 13.9, 14.2, 15. 1, 32.2, 62.2, 62.6, 65.4, 71.7, 112.3, 11 2.5 
115.9, 116.1, 150.3, 157.9, 160.4, 163 .5 165.5, 166.2. 
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Molecular Formulas: C19H24FN04S; Exact Mass Found: 381 .14, Calculated: 381.46. 
2.3.3.9- Ethyl 1-(Cyclopropylmethyl)-7 -fluoro-2-[ ( ethoxymethyl) thio )-quinolin-
4(1H)- one-3-carboxylate (4j) 
This compound was prepared in 90% yield as a yellow oil (6.8 g, 18 mmol) 
employing the same procedure as described for compound 4a, using cyclopropylmethyl 
alcohol (1.44 g, 20 mmol). 
1H NMR (CDCl3): & 0.328-0.358 (2H, d, 1=5.5 Hz) , 0.627-0.664 (2H, d, 1=5.5 
Hz),1.057-1.082 (IH, m), 1.195-1.223 (3H, q, 1=7. 5Hz), 1.421-1.463 (3H, t, 1=7.0 Hz), 
3.637-3.680 (2H, q, 1=7. 0 Hz) , 4.046-4.048 (2H, d, 1=3.0 Hz), 4.454-4.498 (2H, q, 1=7. 0 
Hz), 5.616 (2H, s), 7.203-7.243( 1H, dt, 1=3.0 Hz, 1=9.0 Hz), 7.534-7.561 (lH, dd, 1=3.5 
Hz, 1=1.01 Hz) , 8.127-8.158 (lH, dd, 1=7. 0 Hz, 1=9.5 Hz). 
13 9 C NMR (CDCh): 9.7, 1 0.9, 14.2, 15.1, 58.6, 62.6, 65.4, 71.7, 81.7, 11 2.3, 112.5, 115. , 
116.1, 150.8, 157.8, 160.4, 163.5, 165.4, 166.2. 
Molecular Formula: C19H22FN04S; Exact Mass Found: 379.13 , Calculated: 379.45. 
2.3.3.10- Ethyl 1-(Cyclobutylmethyl)-7 -fluoro-2-[ ( ethoxymethyl)thio ]-quinolin -
4(1H)- one-3-carboxylate (4k) 
Compound 4k was synthesized employing the same method as described for 
compound 4a, using 3a and cyclobutylmethyl alcohol (1.72 g, 20 mmol). The product 
was a colorless oil (7 g, 18 mmol) with a yield of 90%. 
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1H NMR (CDCl3): o 1.193-1.222 (3H, d, J=7. 5 Hz), 1.418-1.469 (3H, m), 1.880-1941 ( 
4H, m), 2. 125-2.156 (2H, m) , 2.803-2 .860 (1 H, m), 3.637-3.678 (2H, q, J=7. 0 Hz), 
4.109-4.186 (21-I, d, J=3.0 Hz), 4.404-4.505 (21-I, q, J =7. 0 Hz), 5.617 (2H, s), 7.187-
7.227( 1H, dt, J =3.0 Hz, J=ll .5 Hz), 7.528-7.551 (IH, dd, J=l .O Hz, J=9.5 Hz), 8.064-
8.094 (lH, dd, J =5.5 Hz, J=9.0 Hz). 
13C NMR (CDCl3): 14.2, 15.1 , 18.4, 21.8, 35.9, 62.6, 65.4, 71.7, 80.8, 111.2, 111.4, 
115.9, 116.1 , 130.5, 150.2, 157.9, 160.4, 163.5, 165.3 , 166.2. 
Molecular Formula: C2oH24F 0 4 ; Exact Mass Found: 393.14, Calculated: 393.47. 
2.3.3.11- Ethyll-(Ailyl)-7-fluoro-2-[ ( ethoxymethyl)thio ]-quinolin-4(JH)-one-3-
carboxylate ( 41) 
This compound was produced utilizing the same procedure as described for 
compound 4a, using 3a (6.5 g, 20 mmol) and allyl alcohol (0.9 g, 20 mmol). The product 
was a colorle s oil (6.6 g, 18 mmol) in 90% yield. 
1H NMR (CDCI3): o 1.200-1.228 (3H, d, J=7. 0 Hz), 1.436-1.463 (3H, q, J=7. 0 Hz), 
3.642-3.685 (2H, q J=7. 5Hz), 4.460-4.488 (2H, q, J=5.0 Hz), 4.644-4 .714 (21-I, d, J=6.0 
Hz), 5.323-5.340 (21-I, d, J=8. 5 Hz), 5.618 (21-I, s), 5.91 (lH, m),7.108-7.133 (IH, dt, 
J=3.5 Hz, J=8.5 Hz), 7.211-7.246 (11-I, dd, J=2. 5 Hz, J=9.5 Hz) 8.060-8.099 (IH, dd, 
J=6.0 Hz, J =9.0 Hz). 
13C NMR (CDCI3): 14.2, 15.1, 62.6, 65.4, 71.6, 74.5 , 11 2.4, 11 5.9, 11 8.7, 125.4, 132.6, 
136.0, 150.3, 157.8, 160.4, 163.5 , 165.5, 166.2. 
Molecular Formula: C 18I-h 0FN04S; Exact Mass Found: 365.1 1, alculated: 365.42; 
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2.3.3.12- Ethyll-Propyn-2-yl-7-fluoro-2- 2-[(ethoxymethyl)thio]-quinolin-4(JH)-
one-3-carboxylate (4m) 
Compound 4m was synthesized in 90% yield (6.5 g, 18 mmol), as a yellow oil, 
employing the same procedure as described for compound 4a, using propargyl alcohol 
(0.84 g, 20 mmol). 
1H NMR (CDCh): 8 1.215-1.247 (3H, d, 1=7. 0 Hz), 1.457-1.550 (3H, q, 1=7. 0 Hz), 
2.269 (lH, s), 3.653-3 .714 (2H, q, 1=7. 0 Hz), 4.527-4.571 (2H, q, 1=4.0 Hz), 5.2 15-
5.252 (2H, p, 1=6.0 Hz), 5.541 (2H, s), 6.835-6.869 (1H, dt, 1=3.0 Hz, 1=8.5 Hz), 7.426-
7.451 (1H, dd, J=2.0 Hz, J=JO.O Hz), 8.166-8.222 (1H, dd, 1=7. 0 Hz, 1=10.0 Hz). 
13C NMR (CDCb): 14.2, 15.1 , 62.6, 65.4, 71.7, 74.4, 112.3, 112.5, 115.9, 116.1 , 126.4, 
135.9, 150.3, 157.9 160.4, 163 .5, 165 .5, 166.2. 
Molecular formula: C 18H 18FN04S; Exact Mass Found: 363.09, Calculated: 363.40. 
2.3.3.13- Ethyl l-(l-Methylnaphthyl)7-fluoro-2-[ ( ethoxymethyl thio )]-quinolin-
4(JH)-one-3-carboxylate (4n) 
This compound was prepared utilizing the same procedure as described for 
compound 4a, using 3a (20 mmol ) and 1-naphthylmethyl alcohol (3 .16 g, 20 mmol). The 
product was a colorless oil (8.37 g, 18 mmol, 90%). 
1H NMR (CDCb): 8 1.113-1.23 1 (3H, t, 1=7. 5 Hz), 1.417-1.426 (3H, t, J=7. 5 Hz), 3.625-
3.647 (2H, q, 1=7.5 Hz), 4.436-4.447 (2H, q, J=7. 5 Hz), 5.244 (2H, s), 5.656 (2H, s), 
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r 
7. 161-7. 171( 1H, dt, 1=2.5 Hz, 1=9.0 Hz), 7.373-7.453 (4H, m), 7.544-7.572 (II-I, dd, 
1=2.0 Hz, 1=9.5 Hz), 7.625-7.745 (3H, m), 7.999-8.029 (II-I, dd, 1=6.0 Hz, J=9.5 Hz). 
Molecular formula: C26H24FN04S; Exact Mass Found: 465 .14, Calculated: 465.54. 
2.3.3.14- Ethyl 1-(2-Methylnaphthyl)-7 -tluoro-2-[ ( ethoxymethyl)thio )-quinolin-
4(1 H)-one-3-carboxy late ( 4o) 
Compound 4o was prepared in 90% yield (8.37 g, 18 mmol), as a colorless oil, 
following the same procedure as described for compound 4m, using 2-naphthylmethyl 
alcohol (3 .16 g, 20 mmol). 
1HNMR (CDCh): & 1.103-1.211 (3H, t, 1=7. 0Hz), 1.399-1.412 (3H, t, J=7. 0Hz), 3.620-
3.634 (2H, q, J=7. 5 Hz), 4.335-4.448 (2H, q, J=7. 5 Hz), 5.2 13 (2H, s), 5.658 (2H, s), 
7.158-7.167 (II-I, dt, J=3.5 Hz, J=9.5 Hz) 7.283-7.389 (4H, m), 7.532-7.564 (lH, dd, 
J=2. 5 Hz, 1=8. 5 Hz), 7.614-7.746 (3H, m), 8.008-8.019 (lH, dd, 1=6. 0 Hz, J=8. 5 Hz). 
Molecular formu la: C26H24FN04S; Exact Mass Found: 465.14, Calculated: 465 .54. 
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2.3.4- Ethyl1-Benzyl-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-carboxylate (Sa) 
To a solution of 4a ( 8.3 g, 20 mmol) in ethanol, two drops of concentrated 
hydrochloric acid was added and stirred at room temperature for 1 0 minutes. The reaction 
mixture was poured into water and the yellow powder was filtered with the yield of 98% 
(7 g, 19.6 mmol). Melting point of the product was not measured and the crude product 
was directly used for the next step of the reaction. 
1H NMR (CDCh): 8 1.439-1.467 (3H, t, 1=6.5 Hz), 4.495-4.537 (2H, q, 1=7. 0 Hz), 5.347 
(2H, s), 6.992-7.030 (IH, dt, 1=2. 0 Hz, 1=8.5 Hz), 7.173-7.195 (lH, dd, 1=2.0 Hz, 1=7. 0 
Hz), 7.399-7.441 (5H, m), 7.870-7.901 (1H, dd, 1= 5.5 Hz, 1=9.5 Hz), 12.079 (lH, s). 
13C NMR (CDCh): 15.1 , 62.6, 102.1, 112.3, 112.5, 115.9, 116.1, 125.4, 125.5, 126.4, 
128.8, 128.9, 136.0, 150.3, 157.9, 160.4, 163.5, 166.2, 180.7. 
Molecular Formula:C19H 16FN03S; Exact Mass Found: 357.08, Calculated: 357.40. 
Employing the same procedure as described for compound Sa and usmg 
compound 4b (8.0 g, 20 mmol), instead of 4a, resulted in production of Sa with the same 
yield. 
2.3.4.1- Ethyl 1-( 4-Fiuorobenzyl)-7 -fluoro-2-mercaptoquinolin-4(1H)-one-3-
carboxylate (Sb) 
Utilizing the same procedure as described for Sa, compound Sb was obtained as a 
yellow powder in 98% yield (7. 28 g, 19.4 mmol) from 4c (8.66 g, 20 mmol). 
1H NMR (CDCh): 8 1.338-1.395 (3H, t, 1=7.5 Hz), 4.483-4.516 (2H, q, 1=7. 5 Hz), 5.356 
(2H, s), 7.063-7.095 (2H, dt, 1=5.5Hz, 1=9. 0 Hz), 7.127-7.167 (1H, dt, 1=5. 0 Hz, 1=ll.5 
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Hz), 7.3 14-7.338 (2H, dd, J =8.5 Hz, J =l0.5 Hz),7.560- 7.573 (lH, dd J =9.5 Hz, J=l3.0 
Hz), 7.938-7.964 (1 H dd, J =8. 0 Hz, J= ll . 0 Hz), 11.089 (1 H, s). 
13C NMR (CDCb): o 15.0, 62.5, 102.0, 112.3, 112.5 114.9, 115.0, 125.4, 125.5, 130.2, 
131.9 131.8 133.0, 150.8, 159.8, 160.1 163.5 166.2 179.1. 
Molecular formula:C19H15F2 0 3S; Exact Mas Found: 375.07; Calculated: 375.39. 
2.3.4.2- Ethyll-(3-Fluorobenzyl)-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-
carboxylate (Sc) 
This compound (7.13 g, 19 mmol, 95%) was obtained as a yellow powder, 
employing the same procedure as described for compound Sa, using compound 4d (8.66 
g, 20 mmol). 
I H NMR (CDCb): o 1.400-1.405 (3H, t, J=7.0 Hz), 4.383-4.416 (2H, q, J=7.0 Hz), 5.358 
(2H, s), 7.053-7.085( 2H, dt, J=4.5 Hz, J=8.5 Hz), 7.137-7.157 (IH, dt, J =4.5Hz, J =l0.5 
Hz), 7.214-7.238 (2H, dd, J=8. 5 Hz, J=ll.5 Hz), 7.560- 7.573 (1H, dd, J=9.0 Hz, J =l4.0 
Hz), 7.938-7.964 (1H, dd, J =7. 5 Hz J=l0.5 Hz),12.350 (lH, s). 
13C NMR (CDCi]): 15.1 , 62.6, 103.1 , 112.4, 112.5, 115.8, 116.0, 125.4, 125.5, 126.4, 
128.8, 128.9, 136.1 150.2, 157.9, 160.3, 163 .5, 166.3, 170.1. 
Molecular formula:C 19H15F2N03S; Exact Mass Found: 375.07; Calculated: 375.39. 
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2.3.4.3- Ethyl 1-(2-Fluorobenzyl)-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-
carboxylate (Sd) 
Compound Sd was made (6.76 g, 18 mmol, 90%), as a yellow solid, from 8.66 g, 
(20 mmol,) of 4e according to the method described for the preparation of Sa. 
1H NMR (CDCh): 8 1.390-1.402 (3H, t, J=7.5 Hz), 4.353-4.426 (2H, q, J=7. 5 Hz), 5.359 
(2H, s), 7.043-7.075 (2H, dt, J =5.5 Hz, J=8.0 Hz), 7.136-7.159 (lH, dt, J=5.0 Hz, 
J=10.5 Hz), 7.214-7.238 (3H, m ), 7.948-7.954 (1H, dd, J=7. 0 Hz, J=J0.5 Hz), 11.560 
(lH, s). 
13CNMR(CDCb): 8 15.0, 62.5 , 104.1 , 112.3, 112.5, 11 5.9, 116.1 , 125.3 , 125.4, 126.4, 
130.8, 130.9, 136.0, 150.3, 157.9, 160.4, 163.5, 165.9, 175.1. 
Molecular formula:C19H15F2N03S; Exact Mass Found: 375.07, Calculated: 375.39. 
2.3.4.4- Ethyll-( 4-Methoxybenzyl)-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-
carboxylate (Se) 
The above compound (7.6 g, 19.66 mmol) was obtained as a colorless powder using 4f 
(9.1 1 g, 20 mmo1) and employing the same procedure as described for Sa. 
1H NMR (CDCb): 8 1.557-1.766 (3H, t, J= 7.8Hz), 3.811 (3H, s),4.51 2-4.499 (2H, q, 
J=7. 9 Hz), 5.367 (2H, s), 7.0 18-7.330 (2H, dt, J=5.0 Hz, J=8.0 Hz), 7.257-7.279 (lH, dt, 
J=5.0 Hz, J =ll .O Hz), 7.404-7.418 (2H, dd, J=8. 0 Hz, J=JO.O Hz),7.632- 7.543( 1H, dd, 
J=8.0 Hz, J =J3.5 Hz), 7.95 1-7.79 (lH, dd, J=8. 0 Hz, J=ll .5 Hz), 12.545 (lH, s). 
13C NMR (CDCb): 8 15.1 , 56.0, 62.6, 103.1 , 112.3, 112.5, 115.9, 116.1, 125.4, 125.5, 
128.8, 128.9, 136.0, 150.3, 157.9, 158.0, 160.4, 163.5, 166.3 , 170.1 
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Molecular Formula : C2oH1sFN04S, Exact Mass Found: 387.09, Calculated: 387.43. 
2.3.4.5- Ethyll-Ethyl-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-carboxylate (Sf) 
Compound Sf (5.4 g, 18.8 mmol, 92%) was made as yellow crystals using 4g (7 
g, 20 mmol) and employing the same method as described for Sa. 
1H NMR (CDC~)): 8 1.420-1.467 (3H, m,), 1.620-1.649 (3H, m), 4.477-4.491 (2H, q, 
1=7. 5 Hz), 5.512-5.563 (2H, q, 1=7. 5 Hz), 7.023-7.138(1H, dt, 1=3. 0 Hz, 1=8. 5 Hz), 
7.616-7.645 (lH, dd, 1=3.0 Hz, 1=8.0 Hz), 8.128-8.158 (lH, dd, 1=5.0 Hz, 1=7.5 
Hz),12.552 (lH, s). 
Molecular Formula: C 14H 14FN03S, Exact Mass Found: 295.07, Calculated: 295.33. 
2.3.4.6- Ethyll-Propyl-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-carboxylate (Sg) 
The title compound was prepared in 97% yield (5.92 g 19.4 mmol) from 4h (7.35 
g, 20 mmol), as a yellow powder, according to the procedure described for Sa. 
1H NMR (CDC13): 8 .1.051-1.061 (3H, m), 1.619-1.639 (6H m), 4.464-4.653 (2H, q, 
1=7. 0 Hz), 5.213-5.375 (2H, q, 1=7. 0 Hz), 7. 11 2-7.134( 1H, dt, 1=3.0 Hz, 1=7.5 Hz), 
7.425-7.545 (lH, dd, 1=2.5 Hz, 1=7.5 Hz), 8.004-8.014 (lH, dd, J=7. 5Hz, 1=8.0 Hz); 
12.345 (1H, s) 
Molecular formula:C 15H 16FN03S, Exact Mass Found: 309.08, Calculated: 309.36. 
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2.3.4.7- Ethyll-Butyl-7-fluoro-2- mercaptoquinolin-4(1H)-one-3-carboxylate (Sh) 
Employing the same technique as described for the preparation of Sa, compound 
Sh was afforded in 94% yield (6.10 g, 18.8 mmol) from 4i (7.62 g, 20 mmol), as a 
yellow powder. 
1H NMR (CDC13): 8 0.987-1.040 (31-I, t, J=7. 5 Hz), 1.310-1.349 (5H, m,), 1.829-1.907 
(21-I, t, J=7. 0 Hz), 4.453-4.673 (21-I, q, J=7. 5 Hz), 5.345-5.363 (21-I, t, J=7. 5 Hz), 7.213-
7.224 (11-I,dt, J=2.5 Hz, J =7. 5 Hz), 7.445-7.459 (11-I, dd, J=2.0 Hz, J=7. 0 Hz ), 8.11 2-
8.153 (11-I, dd, J=7. 5 Hz, J=9.5 Hz), 12.003 (11-I, s). 
13C NMR (CDC h): 13.3, 13.9, 15.1 , 32.2, 62.6, 1 o 1.1 , 112.3, 112.5, 115.9, 116.1 150.3, 
157.9, 160.4, 163.5, 166.2, 172.1. 
Molecular Formula: C1 6HJsFN03S, Exact Mass Found: 323.10, Calculated: 323.38. 
2.3.4.8- Ethyll-Cyclopropylmethyl-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-
carboxylate (Si) 
Compound Si was synthesized employing the same procedure as described for Sa 
by using 4j (7.6 g, 20 mmol).The product was a yellow powder with the yield of 95% 
(6.11 g, 19 mmol). 
11-I NMR (CDCl3): 8 0.350-0.365 (2H d, J =5.5 Hz), 0.636-0.646 (2H, d, J =5.5Hz), 
1.064-1.086 (11-I, m), 1.403-1.435 (3H, t, J=7. 0 Hz), 4.116-4.122 (21-I, d, J=3.0 Hz), 
4.557-4.563 (21-I, d, J=3.5 Hz), 7.270-7.301 (11-I, dt, J=6.5 Hz, J =l5.5 Hz), 7.634-7.65 1 
(lH, dd, J=3.5 Hz, J =8.5 Hz), 8.342-8.381 (IH, dd, J=6.5 Hz, J =J3.0 Hz), 11.932 (IH, 
s). 
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13C NMR (CDCb): 9.7, 10.9, 15.1 , 62.6, 81.7, 101.1 , 112.3, 112.5, 115.9, 116.1 , 150.8, 
157.8, 160.4, 163 .5, 166.2, 220.6. 
Molecular Formula: C16H16FN03S, Exact Mass Found: 321.08, Calculated: 321.37. 
2.3.4.9- Ethyll-Cyclobutylmethyl-7-fluoro-2- mercaptoquinolin-4(1H)-one-3-
carboxylate (Sj) 
This compound was synthesized in 94% yield (6.98 g, 18.8 mol) from 4k (7.86 g, 
20 mmol ) using the same method as described for Sa. The product was a yellow powder. 
1H NMR (CDCb): 8 1.494-1.532 (3H, t, J= 7.5 Hz), 1.906-1960 (4H, m), 2.149-2.188 
(2H, m) , 2.808-2.881 (IH, m), 4.470-4.524 (2H, q, J=7. 0 Hz), 4.559-4.609 (2H, d, J=3.0 
Hz), 7.261-7.298( lH, dt, J=4.0 Hz, J =8.0 Hz), 7.933-7.963 (IH, dd, J =5.5 Hz, J=9.0 
Hz), 8.148-8.177 (lH, dd, J=7. 0 Hz, J =9.0Hz), 12.544 (IH, s). 
13C NMR (CDC13): 8 15.1 , 18.4, 21.8, 35.9, 62.6, 101.1 , 111.2, 111.4, 115.9, 116.1, 
130.5, 150.2, 157.9, 160.4, 163.5, 166.2, 220. 1. 
Molecular Formula: C,7H1sFN03S, Exact Mass Found: 335. 10, Calculated: 335.39. 
2.3.4.1 0- Ethyl 1-AIIyl-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-carboxylate (Sk) 
Compound Sk (5 .5 g, 18 mmol, 90%) was produced as a yellow powder, using 41 
(7.3 g, 20 mmol) and employing the same teclmique as described for Sa. 
1H NMR (CDC13): 8 1.467-1.517 (3H, t, J=7. 0 Hz), 4.544-4.63 1 (2H, q, J=8.0 Hz), 
4.718-4.732 (2H, d, J=7. 0 Hz), 5.413-5.521 (2H, q, J=6.5 Hz),5.81 (IH, m), 7. 11 9-7.150 
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(lH, dt, 1=5.5 Hz, 1=10.0 Hz), 7.590-7.607 (lH, dd, 1=5.0 Hz, 1=8.5 Hz), 8.125-8.153 
(IH, dd, 1=5.5 Hz, 1=10.5 Hz) , 12.556 (IH, s). 
13C NMR (CDCb): 15.1 , 62.6, 105.1 , 112.4, 115.9, 118.7, 125.4, 132.6, 136.0, 150.3, 
157.8, 160.4, 163.5, 166.2, 171.2. 
Molecular Formula: C 15H 14FN03S, Exact Mass Found: 307.07, Calculated: 307.34. 
2.3.4.11- Ethyll-Propyn-2-yl -7-fluoro-2-mercaptoquinolin-4(1H)-one-3-
carboxylate (51) 
Employing the same technique as described for the preparation of Sa, compound 
51 (5.8 g, 19 mmol, 95%) was made using 4m (7.27 g 20 mmol). The product was a 
yellow powder. 
1H NMR (CDCb): & 1.508-1.547 (3H, q, 1=8.0 Hz,), 2.705 (1H, s), 4.527-4.571 (2H, q, 
1=4.0 Hz), 5.414-5.435 (2H, p, 1=7. 0 Hz), 7.388-7.420 (IH, dt, 1=3. 0 Hz, 1=8. 0 Hz), 
7.780-7.817 (IH, dd, 1=3.0 Hz, 1=9.5 Hz), 8.345-8.370 (lH, dd, 1=7. 5 Hz, 1=12.5 Hz), 
12.554 (IH, s). 
13C NMR (CDCb): 15.1 , 62.6, 103.1 , 112.3, 112.5, 115.9, 116.1 , 126.4, 135.9, 150.3, 
157.9, 160.4, 163.5, 166.2, 171.1. 
Molecular Formula: C15H 12FN03S, Exact Mass Found: 305.05, Calculated: 305.33. 
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2.3.4.12- Ethyl1-(1-Naphthylmethyl)-7-fluoro-2-mercaptoquioolio-4(1H)-ooe-3-
carboxylate (Sm) 
This compound was made from 4o (9.31 g, 20 mmol) in 8.0 g (19.66 mmol, 98%) 
yield as yellow powder, using the same procedure as described for Sa. 
1H NMR (CDCb): 8 1.426-1.432 (3H, t, J=7. 0 Hz), 4.542-4.551 (2H, q, J=7. 0 Hz), 
5.454 (2H, s), 7.162-7.172( IH, dt, J=2.5 Hz, J=9. 0 Hz), 7.374-7.458 (4H, m), 7.549-
7.578 (lH, dd, J =2.0 Hz, J=9.5 Hz), 7.646-7.751 (3H, m), 8.011-8.039 (lH, dd J=6.0 
Hz, J=9.5 Hz), 12.345 (lH, s). 
Molecular Formula: C23H 18FN0 3S, Exact Mass Found: 407. 10, Calculated: 407.46. 
2.3.4.13- Ethyl1-(2-Naphthylmethyl)-7-fluoro-2-mercaptoquioolio-4(1H)-ooe-3-
carboxylate (So) 
Compound So was synthesized in 97% yield (7.9 g, 19.4 mrnol), as a yellow powder, 
using 4o (9.3 1 g, 20 mmol) and employing the same technique as used for Sa. 
1H NMR (CDCb): 8 1.398-1.411 (3H, t, J=7. 0 Hz), 4.335-4.449 (2H, q, J=7. 0 Hz), 
5.222 (2H, s), 7.1 59-7.164( IH, dt, J=J.O Hz, J =8. 5 Hz), 7.284-7.388 (4H, m), 7.542-
7.554 (l H, dd, J =2. 5 Hz, J=8. 5 Hz), 7.624-7.736 (3H, m), 8.11 8-8.129 (lH, dd, J=6.0 
Hz, J=8.5 Hz), 12.354 (l H, s). 
Molecular fo rmula: C23H18FN03S, Exact Mass Found: 407.10, Calculated: 407.46 
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2.3.5- 7-Fluoro-9-benzy 1-3-hydroxyisothiazolo [ 4,5-b] q uinolin-4(9H)-one ( 6a) 
To a solution of ethyl 1-benzyl-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-
carboxylate (0.535 g, 1.5 mmol) in 10 mL THF 15 mL sodium bicarbonate solution (5 .7 
g in 100 mL, pH=8) was added, followed by the addition of (0.682 g, 6 mmol) 
hydroxylamine-0-sulfonic acid. The mixture was stirred at ambient temperature 
overnight, then THF was evaporated under reduced pressure. The aqueous filtrate was 
diluted with water and filtered. The crude product was boiled in methanol and the 
supernatant was discarded. Compound 6a was obtained in 95% yield (0.46 g, 1.42 mmol) 
after crystallization from CH2Cb. (mp: 126 °C). 
1H NMR (DMSO-d6): 8 5.847 (2H, s), 7.368-7.416 (3H, m), 7.457-7.529 (3H, m), 7.671-
7.696 (1H, dd, J=2.5 Hz, J=ll.O Hz), 8.253-8.283 (lH, dd, J =6.5 Hz, J=8.5 Hz). 
Molecular formula, C17HIIFN202S; Exact Mass Found: 326.05; Calculated: 326.35. 
2.3.5.1- 7-Fluoro-9-(4-flurobenzyl)-3-hydroxyisothiazolo[4,5-b]quinolin-4(9H)-one 
(6b) 
Compound 6b was prepared as a yellow solid (mp: 130-135 °C) using compound 
5b (0.563 g, 1.5 mmol) and employing the same procedure as that used for the 
preparation of 6a. The yield was 95% (0.488 g, 1.42 mmol). 
1H NMR (DMSO-d6): 8 5.456 (2H, s), 7.363-7.385 (2H, dt, J =5.5 Hz, J =9.0 Hz), 7.427-
7.465 (1H, dt, J=5.5 Hz, J=11.5 Hz), 7.623-7.643 (2H, dd, J =8.5 Hz, J =JO.O Hz),7.859-
7.881( 1H, dd, J=9.5 Hz, J=13.5 Hz), 8.234-8.245 (lH, dd, J=8.0 Hz, J=ll.O Hz). 
Molecular formula:C1 7HIOF2N20 2S, Exact Mass Found: 344.04, Calculated: 344.34. 
79 
2.3.5.2- 7-Fiuoro-9-(3-flurobenzyl)-3-hydroxyisothiazolo[4,5-b)quinolin-4(9H)-one 
(6c) 
Utilizing 5c (0.563 g, 1.5 mmol) and the same procedure as that described for 6a, 
compound 6c was obtained as a yellow solid (0.488 g , 1.42 mmol, 95%,) with the 
melting range of 140-145 °C. 
I H NMR (OM 0-d6): 5.329 (2H, s), 7.338-7.362 (2H, dt, 1=4. 5 Hz, 1=8.0 Hz ), 7.482-
7.512 (lH, dt, 1=4. 5 Hz, 1=10.5 Hz), 7.61 2-7.629 (2H, dd, 1=2. 5 Hz, 1=8. 5 Hz),7.560-
7.590 (lH, dd, 1=9.0 Hz, 1=14.0 Hz), 8.184-8.216 (lH, dd, 1=7. 5 Hz, 1=10.5 Hz). 
Molecular Formula: C17H10F2 20 2S, Exact Mass Found: 344.04, Calculated: 344.34. 
2.3.5.3- 7-Fluoro-9-(2-flurobenzyl)-3-hydroxyisothiazolo [ 4,5-b ]quinolin-4(9Jl)-one 
(6d) 
Compound 6d was synthesized utilizing the same technique a described for 6a as 
a yellow solid from 5d (0.563 g, 1.5 mmol). The yield of the product was 90% (0.463 g, 
1.35 mmol) with the melting range of 145-150 °C. 
1H NMR (DMSO-d6): 8 5.369 (2H, s), 7.044-7.068 (2H, dt, 1=2. 5 Hz, 1=8.0 Hz), 7.23 1-
7.258 (1H, dt, 1=2. 5 Hz, 1=10.5 Hz), 7.458-7.497 (3H, m), 8.038-8.066 (lH, dd, 1=3.0 
Hz, 1=10.5 Hz). 
Molecular Formula: C17H10F2N20 2S, Exact Mass Found: 344.04, Calculated: 344.34. 
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2.3.5.4- 7-Flu oro- 9-( 4-methoxybenzyl)-3-hydroxyisothiazolo [ 4,5-b] q uinolin-4(9 H)-
one (6e) 
This compound was made, as a pale yellow powder, in 90% yield (0.48 g, 1.3 5 
mmol) using Se (0.60 g, 1.5 mmol) and employing the same technique as that used for 6a. 
(mp: 140-1 45 °C). 
I H NMR (CDC13) : 3.902 (3H, s), 5.405 (2H, s), 7.304-7.332( 2H, dt, 1=4.0 Hz, 1=8.0 
Hz), 7.389-7.415 (IH, dt, 1=2.5 Hz, 1=8. 0 Hz), 8.023-8.054 (2H, dd, 1=3.0 Hz, 1=8.0 
Hz), 8.230-8.283( 1H, dd, 1=8.0 Hz, 1=13.5 Hz), 8.345-8.390 (1H, dd, 1=8.0 Hz, 1=11.5 
Hz). 
Molecular Formula: C 1sH 13FN20 3S, Exact Mass Found: 356.06, Calculated: 356.37 
2.3.5.5- 7-Fluoro- 9-ethyl-3-hydroxyisothiazolo[4,5-b]quinolin-4(9H)- one (6f) 
Employing the same technique as described for 6a, compound 6f was obtained in 
95% yield (0.355, g, 1.35 mmol) using Sf (0.443 g, 1.5 mmol). The product was a yellow 
powder. (mp:1 30-135 °C). 
1H NMR (DMSO-d6): 1.563-1.591 (3H, t, 1=7. 0 Hz), 5.867-5.897 (2H, q, 1=7. 5 Hz), 
7.225-7.257( 1H, dt, 1=3.0 Hz, 1=8. 5 Hz), 7.8 16-7.844 (IH, dd, 1=3.5 Hz, 1=8. 0 Hz), 
8.139-8.164 (1H, dd, 1=5.0 Hz, 1=7. 5 Hz). 
Molecular Formula: C12H9FN20 2S, Exact Mass Found: 264.04, Calculated: 264.28. 
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2.3.5-6- 7-Fiuoro-9-propyl-3-hydroxyisothiazolo[4,5-b]quinolin-4(9H)-one (6g) 
This compound (0.373g, 1.35 mmol , 90%) was produced as a pale yellow powder 
(mp: 135- 140 °C) utilizing the same technique as described for 6a and using 5g (0.463 g 
1.5 mmol). 
1H NMR (DMSO-d6): 8 .1.1 51-1.191 (3H, q, J=7. 0 Hz), 1.510-1.539(2H, m), 5.2 15-
5.271 (2H, t, J=7. 0 Hz), 7.202-7.242( IH, dt, J=3.0 Hz, J=7. 5 Hz), 7.623-7.643 (lH, dd, 
J=2.5 Hz, J =7. 5 Hz), 8.114-8.176 (IH, dd, J=7. 5 Hz, J=8. 0 Hz). 
Molecular Formula: C13H, 1FN20 2S, Exact Mass Found: 278.05, Calculated: 278.30. 
2.3.5.7- 7-Fiuoro-9-butyl-3-hydroxyisothiazolo[4,5-b]quinolin-4(9H)-one (6h) 
Utilizing 5h (0.484 g, 1.5 mmol) and the same procedure as described for 6a, 
compound 6h was obtained as a pale yellow solid (0.393 g, 1.35 mmol, 90%). (mp: 145-
150 °C). 
1H NMR (DMSO-d6): 8 0.987-1.040 (3H, t, J =7. 5 Hz), 1.310-1.349 (2H, m,), 1.849-
1.910(2H, m) 5.435-5.495 (2H, q, J =7. 5 Hz), 7.031-7.064( 1H, dt, J=2. 5Hz, J=7. 5 Hz), 
7.287-7.325 ( l H, dd, J=2.0 Hz, J=7. 0 Hz), 8.195-8.234 (lH, dd, J =7. 5 Hz, 1=9.5 Hz). 
Molecular Formula: C14H13F 20 2S, Exact Mass Found: 292.07, Calculated: 292.33. 
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2.3.5.8- 7-Fiuoro-9-cyclopropylmethyl-3-hydroxyisothiazolo[4,5-b]quinolin-4(9H)-
one (6i) 
Compound 6i was made from 5i (0.481 g, 1.5 mmol) in 90% yield (0.39 g, 1.35 
mmol) according to the same procedure as described for 6a. The product was a white 
solid (mp: 145-150 °C). 
1H NMR (DMSO-d6): & 0.450-0.465 (2H, d, 1=7. 5 Hz), 0.636-0.646 (2H, d, 1=5.0 Hz), 
4.558-4.585 (2H, q, 1=13.5 Hz) 5.215-5.265 (1H, m), 7.271-7.302( 1H, dt, 1=6.0 Hz, 
1=15.5 Hz), 7.636-7.652 (lH,d d, 1=3.5 Hz, 1=8.0 Hz), 8.344-8.382 (1H, dd, 1=6.0 Hz, 
1=12.5 Hz). 
Molecular Formula:C 14H 11 FN20 2S, Exact Mass Found: 290.05, Calculated: 290.31. 
2.3.5.9- 7-Fluoro-9-cyclobutylmethyl-3-hydroxyisothiazolo [ 4,5-b] quinolin-4(9 H)-
one (6j) 
Employing the same technique as described for 6a, compound 6j was afforded in 
95% yield (0.43g, 1.42 mmol) from 5j (0.5 g, 1.5 mmol), as a white powd r. 
1H NMR (DMSO-d6): & 1.869-1.934( 4H, m), 2.048-2.080 (2H, q, 1=7. 0 Hz) , 2.810-
2.822 (lH, m),4.654-4.704 (2H, d, 1=3.0 Hz), 7.361-7.483( 1H, m), 8.151-8.213 (lH, dd 
1=6.0 Hz, 1=8.5 Hz), 8.270-8.332 (lH, dd, 1=7. 0 Hz, 1=9.0 Hz). 
Molecular Formula: C15H13FN20 2S, Exact Mass Found: 304.07, Calculated: 304.34. 
83 
2.3.5.1 0- 7-Fluoro-9-allyl-3-hydroxyisothiazolo [ 4,5-b )q uinolin-4(9H)-one ( 6k) 
This compound was obtained in 95% yield (0.39g, 1.42 mmol), employing the 
same technique as described for 6a, using Sk (0.46 g, 1.5 mmol) . The product was a 
white powder. 
1H NMR (DMSO-d6): 8 4.555-5.300 (2H, m ), 5.423-5.634 (lH, m), 5.716-5.724 (2H, q, 
J=6.5 Hz) 7.118-7.148( 1H, dt, J =5.5 Hz, J =JO.O Hz), 7.595-7.612 (lH, dd, J =5.0 Hz, 
J=8.5 Hz), 8.113-8.144 (1H, dd, J=5.5 Hz, J =l0.5 Hz). 
Molecular Formula: C 13H9FN20 2S, Exact Mass Found: 276.04, Calculated: 276.29. 
2.3.5.11- 7-Fiuoro-9-(1-propyn-2-yl)-3-hydroxyisothiazolo[4,5-b]quinolin-4(9H)-one 
(61) 
Compound 61 (1.42, 0.39g, 95%) was made as yellow powder from 51 (0.402 g, 
1.5 mmol) utilizing the same procedure as described for 6a. 
1H NMR (DMSO-d6) : 8 2.71 1 (lH, s), 5.423-5.436 (2H, p, J =7. 0 Hz),, 7.388-7.420 
(lH, dt, J =J.O Hz, J =8.0 Hz), 7.780-7.817 ( l H, dd, J=J.O Hz, J =9.5 Hz), 8.345-8.370 
(1H, dd, J =7. 5 Hz, 1=12.5 Hz ). 
Molecular Formula: C 13H7F 20 2S, Exact Mass Found: 274.02, Calculated: 274.27. 
84 
2.3.5.12- 7-Fluoro-9-(1-naphthylmethyl)-3-hydroxyisothiazolo [ 4,5-b )q uinolin-
4(9H)-one (6m) 
This compound was made from 5m (0.61 g, 1.5 mmol) in 95% yield (0.53g, 1.42 
mmol), according to procedure described for the preparation of 6a. The product was a 
white powder. (mp: 145-150 °C). 
I H NMR (DMSO-d6): 8 5.083 (2H, s), 7.367-7.410(1H, dt, J=2.5 Hz, J=9.0 Hz), 7.511-
7.583 (4H, m), 7.830-7.926 (lH, dd, J=2.0 Hz, J=9.5 Hz), 8.071-8.102 (3H, m), 8.201-
8.218 (lH, d, J=8.5 Hz). 
Molecular Formula: C21H13FN20 2S, Exact Mass Found: 376.07, Calculated: 376.40. 
2.3.5.13- 7-Fluoro-9-(2-naph thy lmethyl)-3-hydroxyisothiazolo [ 4,5-b] q uinolin-4(9H)-
one (6n) 
Compound 6n was synthesized in 95% yield (0.53g, 1.42 mmol), as a white 
powder, from 5n (0.61 g, 1.5 mmol) employing the same technique as described for 6a. 
1H NMR (DMSO): 8 5.224 (2H, s), 7.169-7.164 (1H, dt, J=3.0 Hz, J=8.5 Hz), 7.274-
7.388 (4H, m), 7.533-7.565 (1H, dd, J=2.5 Hz, J=8.5 Hz), 7.635-7.767 (3H, m), 8.118-
8.129 (lH, dd, J=6.0 Hz, J =8.5 Hz). 
Molecular Fomula:C21H 13FN20 2S, Exact Mass Found: 376.07, Calculated: 376.40 
* 
13C-NMR of compounds 6a-n were not measured due to the low solubility of these 
compounds in DMSO-d6 and requirement of long measurement time. 
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2.3.6- Diethyl (2,4-Difluorobenzoyl)malonate (9) 
To a solution of 2,4-difluorobenzoic acid (7) (4.74 g, 30 mmol) in anhydrous 
methylene chloride (CH2Cb) (30 mL) was added oxalyl chloride (7.62 g 60 mmol) and 
one drop of DMF and the mixture was stirred overnight at room temperature . The 
solvent was evaporated under reduced pressure and the resulting 2,4-difluorobenzoyl 
chloride (8) was added dropwise to a suspension of diethyl malonate (4.8 g, 30 mmol) 
and magnesium ethoxide (3.42 g, 30 mmol) in anhydrous ether which was refluxed for 4 
hours before the addition of acid chloride. The reaction mixture was stirred for 2 hours. 
The workup was done under acidic condition with the addition of HCl (lN) to reach the 
pH of 4-5 . The resulting compound was extracted with three portions of ethyl acetate, 
washed with water twice and brine once, dried over sodium sulfate, and evaporated under 
reduced pressure to yield (5.4 g, 18 mmol, 60%) of diethyl (2,4-difluorobenzoyl) 
malonate (9) as a colorless oil. 
lH NMR (CDCb): 81.266-1.299 (6H, m), 3.365 (lH, s), 4.190-4.083(2H, q, 1=7. 5 Hz), 
4 .265-4.308 (2H, q, 1=7.5 Hz), 6.892-6.989 (2H, dd, 1=8.5 Hz, 1=18.5 Hz), 8.037-8 .083 
(lH, dd, J= 6.5 Hz, J= 8.5 Hz). 
Molecular Formula: C 14H 114F20 5; Calculated: 300.25 (inconclusive M measurement). 
2.3.7- Ethyl 2,4-Difluorobenzoyl acetate (10) 
Method A: TsOH (catalytic amount) was added to diethyl (2,4-
difluorobenzoyl)malonate (9) (6.0 g, 20 mmol) in 100 mL of water and refluxed for 4 
hours. The reaction mixture was neutralized with sodium hydroxide (lN) and extracted 
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with ethyl acetate. The organic layer was dried over sodium sulfate, evaporated under 
reduced pressure, and purified by silicagel-column chromatography (hexane: ethyl 
acetate, 20:1) to obtain compound 10 (2.28 g, 10 rnrnol, 50%) as a colorless oil. 
Method B: sixty percent sodium hydride suspension in mineral oil (0.82 g, 20.5 
rnrnol) was added slowly at room temperature to a cold solution of (1.5614 g, 10mmol) 
2,4-difluroacetophenone (11) in diethyl carbonate (30 mL). The mixture was heated at 
80°C for 1.5 h. It was poured into ice-cooled water (70 mL) containing acetic acid (2 .5 
mL). The mixture was then extracted with ethyl acetate. The organic phase was dried 
over sodium sulfate , evaporated under reduced pressure and the residual oil was distilled 
at 111 °C (0. 7 rnrnHg) to give (1.83 g, 8 mmol, 80% yield) of compound 10 as a white, 
low melting point solid. The spectral data and TLC profiles of the compounds obtained 
by both methods were similar. 
1H NMR(CDCb): 8 1.490-1.518 (3H, t, J =7.0 Hz), 3.950-3.958 (1.5H, d, J=4. 0 Hz), 
4.097-4.138 (2H, q, J=7. 0 Hz),5.796 (0.3H, s), 6.870-7.037 (2H, m),7.983-8.031 (1H, 
dd, J=6.5 Hz, J=8.5 Hz), 12.720 (0.2H, s). 
Molecular Formula : C 11H 10F20 3, Calculated: 228.19 (inconclusive MS measurement). 
2.3.8- Ethyl (2Z)-3-(Benzylamino)-2-(2,4-difluorobenzoyl)-3-(methylthio)acrylate 
(12) 
Sixty percent sodium hydride suspension in mineral oil (0.96 g, 24 mmol) was 
added slowly under nitrogen atmosphere to an ice-cooled solution of 10 (4.56 g, 20 
mmol) and N-benzylisothocyanate (2.98 g, 20 mmol) in 30mL of anhydrous DMF. After 
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the addition of sodium hydride was completed, the reaction mixture was allowed to warm 
up to 35 °C and stirred for 48 hours. Methyl iodide (2.84 g, 20 mmol) was added to the 
reaction mixture at 3 5 °C and after 24 hours, 2 mL of glacial acetic acid was added, then 
the solvent was removed under reduced pressure. The residue was dissolved in methylene 
chloride and the solution was washed with brine, dried over sodium sulfate, filtered, and 
concentrated under reduced pressure. The residue was purified by silicagel column 
chromatography, using ethyl acetate (1 %) in methylene chloride, as an eluent, to obtain 
compound 12 as a yellow oil (0.79 g, 2 mmol,10%). 
1H NMR (CDCh): & 0.909-0.936 (3H, t, J=6.5 Hz) , 2.306 (3H, s), 3.919-3 .962 (2H, q, 
J=6.5 Hz), 5.296 (2H, s), 6.756-6.795(lH, m), 6.862-6.889( 1H, m) 7.308-7.389( 5H, m) 
7.482-7.527(1H, m), 11.705 (1H, s). 
Molecular Formula: C20H 19F2N03S, Calculated: 391.43 (inconclusive MS measurement). 
2.3.9- Ethyl1-Benzyl-7-fluoro-2-methylthioquinolin-4(1H)-one-3-carboxylate (13a) 
First method: to a solution of 12 (3.91g,10mmol) in 50mL ofTHF, 60% sodium 
hydride in mineral oil (0.8 g, 20 mmol) was added . The reaction mixture was heated at 
reflux for 48 hours, then lmL of glacial acetic acid was added. The solvents were 
removed under reduced pressure and the residue was dissolved in methylene chloride. 
The methylene chloride solution was washed with water, dried over anhydrous 
magnesium sulfate, and concentrated under reduced pressure to obtain 13a (2.71 g, 7 
mmol, 70%) as a yellow crystal. (mp: 145-150 °C). 
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Second method: 
To a solution of 3c (5.62 g, 20 mmol), benzyl alcohol (2.16g,20 mmol), triphenyl 
phosphine (6.29 g, 24 mmol) in THF (30 mL), diisopropyl azidodicarboxylate (DIAD) 
(4.85 g,24 mmol) was added dropwise and the mixture was stirred overnight at room 
temperature. The crude product was dissolved in ethyl acetate (40 mL) and washed with 
three portions of brine solution (1 0 mL). The solution was dried over sodium sulfate and 
evaporated to dryness. The resulting compound was pmified using a short silicagel 
column (hexane: ethyl acetate, 10:1) to yield 13a (6.7g, 18 mmol, 90%) as a yellow 
crystal. (mp: 145-150 °C). The products obtained by the above methods possessed similar 
spectral and physical characteristics. 
1H NMR (CDCb): 8 1.521-1.548 (3H, t, J =7. 0 Hz), 2.586 (3H, s), 4.530-4.572 (2H, q, 
J =7. 0 Hz ), 5.161 (2H, S),7.132-7.170 (II-I, dt, J =2. 0 Hz, J=8. 5 Hz),7.391-7.445 (5H, m), 
7.531-7.556 (II-I, dd, J =2.0 Hz, J =JO.O Hz), 8.201-8.230 (1H, dd, J =5.5 Hz, J =8.5 Hz). 
Molecular Formula: C20H 18FN03S, Calculated: 371.43 (inconclusive MS measurement). 
2.3.9.1- Ethyl 1-( 4-Fluorobenzyl)-7-fluoro-2-methylthioquinolin-4(1H)-one-3-
carboxylate (13b) 
Compound 13b was prepared employing the second method as described for the 
preparation of 13a, using 3c (5.62 g, 20 mmol) and 4-fluorobenzyl alcohol (2.5 g, 20 
mmol). The product was a yellow oil and the yield was 95% (7.39 g, 19 mmol). 
1H NMR (CDCh): 8 1-379-1.433 (3H, m), 2.675 (3H, s) ,4.441-4.483 (2H, q, J =7. 0 Hz), 
5.177 (2H, s), 7.083-7.111 (2H, m), 7.148-7.187(1H, dt, J =2.0 Hz, J =7. 0 Hz), 7.404-
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7.428 (2H, m), 7.540- 7.563 (lH, dd, J =2.0 Hz, J =9.0 Hz), 7.945- 7.977 (lH, dd, J =7. 0 
Hz, J=2. 0 Hz). 
Molecular Formula: C2oH 17F2N03S, Calculated: 389.42 (inconclusive MS measurement). 
2.3.9.2- Ethyl 1-( 4-Methoxybenzyl)-7-fluoro-2-methylthioquinolin-4(1H)-one-3-
carboxylate (13c) 
This compound was afforded utilizing the second method as described for 13a, 
using 3c (20 mmol, 5.62 g) and 4-methoxybenzyl alcohol (20 mmol,2.76 g). The yield 
was 95% (7.6 g, 19 mmol) and the product was a yellow oil . 
1H NMR (CDCh) 8: 1.405- 1.436 (3H, m), 2.674 (3H, s) 3. 832 (3H, s), 4.435-4.470 
(2H, q, J =7. 0 Hz), 5.147 (2H, s ), 6.917-6.945 (2H, m), 7.126- 7.166 (lH, dt, J =2.5 Hz, 
J =8.5 Hz) , 7.344- 7.362 (2H, m ), 7.523- 7.548 (1H, dd, J =2. 5 Hz, J = 9.5 Hz), 7.960-
7.991 (lH, dd J = 7. 0 Hz J= 9.5 Hz) . 
Molecular Formula: C21H2oFN04S, Calculated: 401.45 (inconclusive MS measurement). 
2.3.9.3- Ethyll-Heptyl-7-fluoro-2-methylthioquinolin-4(1H)-one-3-carboxylate (13d) 
Compound 13d was prepared utilizing the second method as described for 13a, 
using heptyl alcohol (2.32 g, 20 mmol) and 3c (5.62 g, 20 mmol). The yield was 80% (6 
g, 16 mmol) and the product was a yellow oil. 
1H NMR (CDCh) 8: 0.870-0.906 (3H, t, J =6. 0 Hz), 1.256-1.298 (3H, t, J =7. 0 Hz ), 1.411-
1.501 (lOH, m), 2.656 (3H, s), 4.173-4.198 (2H, t, J=6.0 Hz), 4.437-4.494 (2H, q, J= 7. 5 
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Hz), 7.173-7.213 (1H, dt, J= 2.5 Hz, J= 9.0 Hz), 7.511-7.537 (1H, dd, J = 2.5 Hz, J =8.0 
Hz), 8.051- 8.080 (1 H , dd, J= 6. 0 Hz, J=3. 0 Hz). 
Molecular Formula: C20H26FN03S, Calculated: 379.49 (inconclusive MS measurement). 
2.3.9.4- Ethyll-Cyclopropylmethyl-7-fluoro-2-methylthioquinolin-4(1H)-one-3-
carboxylate (13e) 
Using the same condition as utilized in preparation of compound 13a, compound 
13e (6g, 18 mmol, 90%) was obtained from 3c (5 .62 g, 20 mmol) and cyclopropylmethyl 
alcohol (1.44 g, 20 mmol) as a yellow oil. 
1H NMR (CDC13) 8: 0.681- 0.702 (2H, m), 0.977- 0.993 (2H, m), 1.637- 1.673 (1H, m), 
1.785- 1.811 (3H, t, J= 7. 0 Hz), 3.000 (3H, s), 4.375- 4.389 (2H, d, J= 7.0 Hz), 4.803-
4.846 (2H, q, J= 7. 0 Hz), 7.517- 7.557 (1H, dt, J= 2.5 Hz, J = 8. 5 Hz), 7.852- 7.871 (11-I, 
dd, J=3.0 Hz, J= 9.5 Hz), 8.447- 8.478 (1H, dd, J= 2.0 Hz, J= 6.5 Hz). 
Molecular Formula: C 17H 1sFN03S, Calculated: 335.39 (inconclusive MS measurement). 
2.3.9.5- Ethyll-Cyclobutylmethyl-7-fluoro-2-methylthioquinolin-4(1H)-one-3-
carboxylate (13f) 
Using the same method, as described for 13a, and cyclobutylmethyl alcohol (1 .72 
g, 20 mmol), compound 13f was obtained in 90% yield ( 6.28 g, 18 mmol) as a yellow oil. 
1H NMR (CDCh) 8: 0.968-0.972 (2H, m), 1.261-1.300 (lH, m), 1.426- 1.470 (3H, m), 
1.877- 1.923 ( 4H, m), 2.672 (3H, s), 4.116- 4.130 (2H, J= 7. 0 Hz), 4.460- 4.501 (2H, q, 
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J=6.5 Hz) , 7.176- 7.206 (lH, dt, J= 3.0 Hz, J=9.5 Hz), 7.513- 7.537 (lH, dd, J = 3.0 Hz, 
J= 6.5 Hz), 8.053- 8.084 (lH, dd, J=2.0 Hz, J= 6.5 Hz). 
Molecular Formula: CtsH2oFN03S, Calculated: 349.42 (inconclusive MS measurement). 
2.3.9.6- Ethyl 1-(1-Prop-2-yn-1-yl)-7 -fluoro-2-methylthioquinolin-4(1.H)-one-3-
carboxylate (13g) 
This compound was synthesized by the same method as employed for 13a, using 
prop-2-yn-1-ol (1.12 g, 20 mmol) and 3c (5.62 g, 20 mmol). The yield was 85% (5.42 g 
17 mmol) and the product was a yellow oil. 
1H NMR (CDC13): & 1.457-1.550 (3H q, J=7 Hz), 2.102 (1H, s), 2.269 (3H, s), 4.327-
4.371 (2H, q, J =4.0 Hz), 4.541 (2H, s), 6.835-6.869( 1H, dt, J =3.0 Hz, J =8.5 Hz), 7.426-
7.451 (1H, dd, J =2.0 Hz, J=JO. 0 Hz), 8.166-8.222 (1H, dd, J =7. 0 Hz, J =JO.O Hz) . 
Molecular Formula: C16H14FN03S Calculated: 319.35 (inconclusive MS measurement). 
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2.3.1 0- Ethyl 1-Benzyl-7-fluoro-2-methylsulfinylquinolin-4(1H)-one-3-carboxylate 
(14) 
To an ice cooled suspension of 13a (7.75 g, 20 mmol) in 30 mL of methylene 
chloride, m-chloroperbenzoic acid (MCPBA) (3 .4512 g, 20 mmol) was added and the 
mixture was stirred for an hour. The crude product was extracted with 20 mL of diethyl 
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ether, washed with water, dried over sodium sulfate and evaporated under vacuum to get 
compound 14 ( 4 g, 10 mmol, 50% yield) as a white powder (mp: 127 °C). 
1H NMR (CDCI3) : 8 1.403-1.440 (3H, t, 1=6.0 Hz), 3.007 (3H, s), 4.528-4.570 (2H, q, 
1=7. 0 Hz) , 5.147 (2H, S),7.133-7.171 (1H, dt, 1=2.0 Hz, 1=8.5 Hz),7.381-7.435 (5H, m), 
7.534-7.560 (lH, dd, 1=2.0 Hz, 1=10.0 Hz), 8.209-8.238 (lH, dd, 1=5.5 Hz, 1=8.5 Hz). 
Molecular Formula: C2oH1sFN04S, Mol. Wt.: 387.43 (inclusive MS measurement) 
2.3.11- Ethyl1-Benzyl-7-fluoro-2-mercaptoquinolin-4(1H)-one-3-carboxylate (Sa) 
To a solution of compound 14 (2 g, 5 mmol) in 50 mL of THF at 60 °C, NaSH 
(0.21 g,5 mmol) was added under nitrogen. The solution was stirred overnight and the 
reaction was quenched by lmL of glacial acetic acid. The reaction mixture was dissolved 
in diethyl acetate, washed several times with water, once with brine solution, dried over 
sodium sulfate, evaporated under reduced pressure, and purified by column 
chromatography (hexane:ethyl acetate, 7:1) to yield compound Sa as a yellow crystal 
(0.373 g, 1 mmol, 20%). mp: 135-140 °C. 
1H NMR (CDCh): 8 1.439-1.467 (3H, t, 1=6.5 Hz), 4.495-4.537 (2H, q, 1=7.0 Hz), 5.347 
(2H, s), 6.992-7.030 (1 H, dt, 1=2.0 Hz, 1=8. 5 Hz), 7.173-7.195 (I H, dd, 1=2. 0 Hz, 1=7.0 
Hz) , 7.399-7.441 (5H, m), 7.870-7.901 (lH, dd, 1= 5.5 Hz, 1=9.5 Hz), 12.079 (IH, s). 
13C NMR (CDCh): 8 15.0, 62.5, 104.1 , 112.3, 112.5, 115.9, 116.1 , 125.3, 125.4, 126.4, 
130.8, 130.9, 136.0, 150.3, 157.9, 160.4, 163.5, 165.9, 175.1. 
Molecular Formula:C 19H16FN03S; Exact Mass Found: 357.08, Calculated : 357.40. 
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2.3.12- Cytotoxicity screening 
The cytotoxicities of selected final products and intermediates synthesized in this 
study were preliminary screened by Dr. S-Q Cai ' s group at the School of Pharmaceutical 
Sciences, Peking University, P.R. China. The assessment was performed by this group 
using a protocol designed for high-throughput preliminary screening of natural and 
synthetic cytotoxic agents. Based on this protocol, all the drugs were tested at a 
concentration of 100 J..tg/mL. The method used and the results are described as following. 
The cell lines used were: human leukemia cancer cell line (HL-60); human gastric 
cancer cell line (BGC-823); human breast cancer cell line (MDA-MB-435); human 
cervical cell line (Hela), and human hepatocellular carcinoma cell line (Bel-7402). 
The in vitro HL-60 tumor cell assay was carried out according to the procedure reported 
by Twentyman, et a!. 121 BGC-823, Bel-7402, and HeLa tumor cell assays were carried 
out by a sulforhodamine B (SRB) assay method. 122 A cell suspension in the culture 
medium (4x104 cells/mL) was inoculated in a 96-well microtiter plate. One day after 
seeding, a control plate at time zero was made. In the presence or absence of the test 
compounds, the cells were incubated for a further 48 h in a 5% C02 incubator at 37 °C. 
Cells were fixed with 50 J..ll of 20 % trichloroacetic acid solution for 1 h at 4 oc and plates 
were washed 5 times with tap water and air-dried. A 50 f..ll of SRB solution (0.4% in 1% 
acetic acid) was added and kept at room temperature for 30 min. The residual dye was 
washed out with 1 % aqueous acetic acid and air-dried. To each well, Tris buffer solution 
(10 mM, pH= l0.5) was added. Optical density (OD) was measured with a microtiter plate 
reader at 540 nm. Growth inhibition was calculated as follows: 
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%inhibition== [1-(0D value for treated cells/ OD value for untreated cells)]lOO% 
The structures of the tested compounds are depicted in Figure 2.4 and the results are 
summarized in Table 2.1. 
0 
SCH, F 
4d 13a,b,f 6n,c,k 
No. R1 R, 
13a UCH,- 6a U CH,-
13b JYCH,- 6c ~CH,-
F F 
13f ~H,. 6k ~H,· 
Figure 2.4- Structure of the compounds tested 
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Table 2.1- Preliminary cytotoxicity screening results 
Percentage of inhibition on different cell lines at 100 ~g/mL 
HL-60 PC-3M- BGC- MDA- Bel-7402 He La 
(Human 1E8 823 ME (Human (Human 
Compounds leukemia (prostate (Human (Human hepatocellular cervical 
cancer cell line) cancer gastric leukemia carcmoma cell 
cell line) 
cell line) Cancer cell line) line) 
cell line) 
13a -9.42 -10.75 -6.21 0.23 -0.72 -14.86 
13b 37.19 5.81 1.22 19.42 -10.12 -3.59 
13f 9.78 -15.96 0.02 3.00 -1.43 -9.30 
6a 10.23 -7.38 0.94 2.33 12.10 -6.44 
6c 41.37 -10.19 0.44 16.95 2.16 13.36 
6k 11.40 -10.58 -1.38 4.47 1.59 -0.38 
4d 10.12 -13.19 -2.94 -10.60 1.46 -6.60 
*Negative signs denote proliferation 
* No signs denote inhibition 
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3- Discussion 
As per the descriptions in Section 2.3 (Methods and Results), the objective of this 
research was to design and synthesize linear tricyclic isothiazoloquinolones that are 
bioisosterically related to the angular thiazoloquinolone A (Figure 2.1 in page 50) and 
possess the same biological activity profile as that of compound A while being less acidic 
and tolerable if taken by oral route. Compound A had exhibited favorable drug-like 
properties in different animal models in preclinical studies .130 
Structure-based drug design approach was employed to initially design the 
isothiazolo-quinolones, using Alchemy-3 ™ software on an Octane-2 Silicon Graphic 
system. The computational chemistry was performed by Dr. Alan Cameron of SynPhar 
Laboratories Inc., Edmonton, Alberta, Canada. Using Molecular Mechanics Optimization 
(MMO) and Molecular Dynamics Option models, the energetically optimized 
configuration of compound A was first determined. The bioisosteric linear 
isothiazoloquinolones were then designed based on the energetically minimized structure 
of compound A, as described in Section 2.3. In this respect, compound B (6a), at its 
optimized steric/energetic configuration, was identified as a molecule with a perfect 3-
point overlay with compound A (Figures 2.2 and 2.3 in page 51). 
In order to pursue the synthesis of compound B and its N-1 substitued analogues, 
we first attempted the modified Gould-Jacobs quinoline synthesis, based upon a 
hypothetical retrosynthetic pathway as described in pages (53-84). The retrosynthetic 
pathway hypothesized for the synthesis of compound B and its N 1-substituted analogues 
(6a-n) is depicted in Scheme 3.1. Starting from 3-fluorobenzylisothiocyanate, diethyl 
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malonate, and an appropriate alkyl halide, compound 2a-c are expected to form, further 
Gould-Jacob type ring closure of which would result in the formation of compounds 3a-c. 
Benzylation of this compound gives rise to compounds 4a-o which after S-dealkyation 
affords compounds Sa-n. The final step in this procedure is the formation of the third ring 
via reaction of compounds Sa-n with hydroxylarnine-0-sulfate to obtain the desired 
compounds 6a-n. 
F N 
I 
R2 
6a-n 
OH 
F 
3a-c 
0 
===:::? 
F 
Sa-n 
0 0 HsC20~ 
OC2Hso OCH I I 2 s 
SR ===:::? # ===:::? 
F N SR1 
H 
2a-c 
0 
N 
I 
R2 
4a-o and 13a-g 
+ 
<C02C2H5 
+ C02C2H5 
X-R1 
Scheme 3.1- Retrosynthetic pathways hypothesized for the synthesis of compound B (6a) 
In practice, several key steps in this synthetic approach were identified that affect 
the yields as well as the synthetic feasibi lity of the intermediates and the final 
compounds. The formation and the yields of compounds Sa-n were mainly dependent on 
the nature of R in compounds 4a-o. In the case of R2 = CI-hOCH2CH3, the S-dealkyation 
was easily achieved in 90-98% yields by the acid hydrolysis of compounds 4a-o at room 
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temperature, as shown in Scheme 2.5 (page 69) and described in Sections 2.3.4- 2.3.4.13. 
In case of R = CH3 (13a, page 90), de-methylation of S required an initial oxidation of 
13a to 14, followed by substitution of the sulfinyl group of 14 to afford the thiol Sa in 
overall 10% yield from 13a via treatment with sodium hydrosulfide as depicted in 
Scheme 2.8 (13a, page 90) and described in sections 2.3.1 0- 2.3.11. 
Preparation of compounds of the 4a-o and 13a-g series was a challenging step. In 
fact, direct benzylation of compound 3c resulted in the formation of both N-and 0-
benzylated products and which were isolated by column chromatography in yields below 
1 0% (Scheme 3 .2). 123 
3c 
F 
Scheme 3.2- Direct benzylation of compound 3c 
In order to avoid non-selective alkylation reactions, compounds 4a-o and 13a-g 
were synthesized via either regioselective alkylation of compounds 3a-c employing a 
modified Mitsunobu reaction using the appropriate alcohol, as shown in Scheme 2.3 
(page 55) and described in sections 2.3.3- 2.3.3.14, or modified Gould-Jacobs method as 
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depicted in Schemes 2.7, 2.8 (page 86) and (page 87), and described in sections 2.3.6 -
2.3.9.6. 124-125 
As shown in Figure 2.8 (page 87), regioselective N-1 alkylation of compounds 3a-
c, using a modified Mitsunobu method, proceeded smoothly at room temperature to 
afford compounds 4a-o in 88-98% yields. Synthesis of compounds 13a-g took a lengthy 
course during which the corresponding compounds were made in several steps from a 
general intermediate, 2,4-difluorobenzoyl acetoacetate (10). Compound 10 was either 
prepared from 2,4-difluorobenzoic acid (7) in three steps and in an overall yield of 54%, 
or from 2,4-difluoroacetophenone (11) in 95% yield. Condensation of compound 10 with 
the appropriate isothiocyanate, followed by methylation, yielded the intermediate 12, 
which upon cyclization afforded compounds 13a-g in 70 - 95% yields. These compounds 
were also prepared in one step via Mitsw1obu alkylation of 3c in 80-95% yields (Figure 
2.8, page 87). 
With respect to the synthetic feasibility of compounds Sa-n from either the 4a-o 
or the 13a-g series, the following conclusions can be made. 
Syntheses of Sa-n by the procedure (Scheme 2.1 ) starting from 
phenylisothiocyanate (1) to make compound 3a fo llowed by regioselecive Mitsunobu 
alkylation of this compound to 4a-o (excluding 4b), which are readily deprotected by 
acid hydrolysis to the desired compotmds Sa-n (excluding Sb) results in short synthetic 
steps and an overall yields of 56 - 84%, respectively. 
The yields of compounds Sa-n, obtained via 13a-g, were mainly dependent on the 
synthetic routes employed to make compounds 13a-g and their fur1her oxidations and 
103 
nucleophilic substitutions of the sulfinyl group to the thiols. Compounds 13a-g were 
prepared by two distinct synthetic methods. The first method comprised preparation of 
compound 10 (Scheme 2.7, page 86) in yield of 54% (from 7) and 95% (from 11), which 
via intermediate 12 followed by cyclization afforded 13a in an overall yield of 22.7% 
from 7 and 40% from 11, respectively, as described in previous paragraph. 
In the second method (Scheme 2.8, page 87), compounds 13a-g were synthesized 
in one step via Mitsunobu alkylation reactions of 3c in 80 - 95% yields, respectively. 
As described previously, transformation of 13a, the representative compound of 
this series, into Sa required two steps, first oxidation by m-PCBA to the corresponding 
sulfinyl derivative 14 followed by a substitution reaction with sodium hydrosulfide, as 
shown in Scheme 2.9 (page 95) and described in sections 2.3.10 and 2.3.11. 
Unfortunately, the overall yield of these two steps was 10%, compared with that of Sa 
when compound 4a underwent acid hydrolysis to afford the san1e compound in 98% 
yield (Scheme 2.5, page 69). 
Comparing the above-discussed routes for the synthesis of compounds 6a-n, and 
taking the synthetic steps and overall yields into consideration, the following route is 
proposed as the most feasible for the synthesis of6a-n as shown in cheme 3.3. 
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I 
R 
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Scheme 3.3- The most feasible synthetic routes for compounds 6a-n 
Thus, Gould-Jacobs ring closure of 2a to 3a followed by Mitsunobu alkylation 
using a variety of alcohols gives rise to compounds 4a-o. Simple acid hydrolyses of 4a-o 
affords the mercapto derivatives Sa-n in high yields. Ring closure of Sa-n using 
hydroxylamine-0-sulfate, affords compounds 6a-n in high yields. According to the above 
Scheme and based on compound 1, the overall yields of compounds 6a-n is 54-70% in 
five steps, while with other pathways the overall yields are below 10% and require longer 
steps. 
In order to explore the cytotoxicity potential of these compounds, selected final 
products and intermediates were tested by Dr. S-Q Cai's group at the School of 
Pharmaceutical Sciences, Peking University, P.R. China. As mentioned in Section 2.3 .12, 
the assessment was performed by this group using a protocol designed for high-
throughput preliminary screening of natural and synthetic cytotoxic agents. We had no 
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say in the selection of the cell lines as well as the minimum concentration of the test 
compounds to evaluate the percentage of the viable cells. Due to the preliminary 
screening nature of the protocol used by Dr. Cai's group, the TD50 values of the tested 
compounds were not measured and the percentage of viable cells were determined at 100 
11g/mL, instead. Also, no reference compound was used for comparison in their assays. 
Therefore, the results presented in Section 2.3.12 are based on a random screening on 
specific cancer cell lines whose sensitivities toward topoisomerase inhibitors are not 
defined. The following discussion is based on the preliminary results provided by Dr. 
Cai's group. 
Four quinolone carboxylate analogues (13f, 13b, 13a, and 4d) and three i o-
thiazoloquinolone analogues (6a, 6c, and 6k) were tested for their cytotoxic effect. ln 
HL-60 leukemic cell line, the 13b and its isothiazoloquinolone analogue 6c exhibited 
cytotoxic effect with 37.19 and 41.37 % inhibitory activity at 100 flg/mL concentration, 
while 13f, its isothiazoloquinolone analogue 6k, and 4d exhibited cytotoxicity in the 
range of 9.78 to 11.40% at the same concentration. Surprisingly, the intermediate 
compound 13a showed proliferative activity. In PC-3M- IE8 prostate cancer cell lin , 
except for the intermediate compound 13b which was weakly inhibitory, the other 
compounds were proliferative. In BGC-823 human gastric cell line, these compounds 
were either weakly inhibitory (13f, 13b, 6a, and 6c) or weakly proliferative (13a, 4d, and 
6k). In MDA-ME human leukemic cell line, both compounds 13b and its 
isothiazoloquinolone analogue 6c exhibited stronger inhibitory activity while 13f, 13a, 
6a, 6k were weakly inhibitory and 4d was proliferative. The most interesting results were 
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observed when these compounds were tested against Bel-7402 human hepatocellular 
carcinoma cells. While the intermediates 13f, 13b, and 13a exhibited proliferative 
activity, the isothiazoloquinolone analogue of 13a (6a) exhibited a mild inhibitory 
activity (12.1 0% at 100 11g/mL concentration), and 6c (the isothiazoloquinolone analogue 
of 4d) and 6k (the isothiazoloquinoline analogue of 13f) exhibited a very weak inhibitory 
activity against this cell line at 100 11g/mL concentration. Finally, as expected, except for 
compound 6c, all the other intermediates and final products exhibited proliferative 
activity against HeLa cell line. 
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4- Conclusions 
The design and syntheses of a senes of 7-fluoro-9-substituted-3-
hydroxyisothiazolo[ 4,5-b ]quinolin-4(9H)-one derivatives (6a-n) were explored in this 
study using different synthetic approaches. The most feasible synthetic approach was 
selected based on the short number of steps, ease of synthesis, availability of the required 
starting materials and intermediates, and the stepwise yields. Based on the above criteria, 
we successfully synthesized 14 derivatives (6a-n) in 5 steps and overall yields of 54-70% 
as described in Section 3 and shown in Scheme 3.3 (page 1 05). Selected final compounds 
and intermediates were tested by Dr. Cai's group at the School of Pharmaceutical 
Sciences, Peking University, P.R. China. for their cytotoxic potential. 
Despite observation of cytotoxic/proliferative effects of the tested compounds 
against the cell lines used in the assessment, the real anticancer potential of these 
compounds can not be concluded due to the following factors: (a) test results were only 
based on a single concentration of 100 11g/mL; (b) unavailability of toxicokinetic data 
including TD50 values; (c) unavailability of topoisomerase inhibitory profiles of these 
compounds, and (d) the low number of compounds tested. These preliminary results may 
indicate some cytotoxic potential of this class of compounds, but a more detailed 
structure-activity relationships study is needed to confirm this hypothesis. 
Considering the structural difference between compound A, an angular thiazoloquinolone, 
and compound B (6a and its analogues), a linear isothiazoloquinolone, the more 
hydrophilic characteristics of 6a-n, compared to that of compound A, may attribute to 
their weak cytotoxic profile or proliferative activity. On this basis, we hypothesize that 
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thienoquinolones, such as compound C (Figure 4.1) that should possess physicochemical 
properties similar to that of compound A, might exhibit potential anticancer activities. 
Therefore further studies on molecules related compound C is warranted. 
0 0 0 
0 
I 
OH 
~ ~N F crs I F N 
s 
F N s \) \) 
Compound A Compound B Compound C 
Figure 4.1- Structures of compound A, B, and C 
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